f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom troper ecnanif e roche finance report finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business free cash flow concept fully described pages reconciliations ifrs cash flow free cash flow given therefinance report roche group finance brief roche roche group reported solid overall results underlying business showing resilience pandemic environment sales grew constant exchange rates cer ifrs net income increased cer core earnings per share increased cer appreciation swiss franc almost currencies adverse impact results expressed swiss francs sales group sales increased cer chf billion decline chf terms pharmaceuticals sales declined cer mainly due impact biosimilars notably us impacts covid pandemic leading reduced hospitalisations outpatient visits growth new medicines led tecentriq hemlibra ocrevus perjeta kadcyla additional sales actemraroactemra partly compensated declines diagnostics sales showed growth cer due sales covidrelated tests notably cobas sarscov pcr test sarscov rapid antigen test offset decline routine testing across portfolio operating results core operating profit increased cer chf billion decline chf terms research development expenditure grew cer chf billion core basis despite pandemic environment focus oncology neuroscience immunology therapeutic areas research development costs represented group sales ifrs operating results included noncore expenses pretax chf billion major factors chf billion amortisation charges intangible assets chf billion restructuring costs chf billion impairment goodwill intangible assets release litigation provisions resulted income chf billion nonoperating results financing costs ifrs decreased cer chf billion due early debt redemption losses chf billion lower interest expenses income tax expenses ifrs increased cer chf billion effective core tax rate increased mainly due impacts resolution several tax disputes net income ifrs net income increased cer chf billion chf terms driven operating results core earnings per share increased cer chf chf terms cash flows operating free cash flow chf billion decrease cer underlying cash generation remained strong decrease cer arising increases net working capital higher investments inlicensing alliance arrangements free cash flow decreased cer chf terms chf billion driven lower operating free cash flow financial position net working capital increased cer driven increases inventories divisions net debt decreased chf billion chf billion free cash flow offset dividends paid outflows transactions equity instruments gross debt increased cer chf billion credit ratings remained strong moodys aa standard poors aa shareholder return proposal made increase dividends chf per share would represent th consecutive year dividend growth would result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity security roche group finance report roche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles current liabilities operating segment information provisions contingent liabilities revenue debt net financial expense equity attributable roche shareholders income taxes subsidiaries mergers acquisitions noncontrolling interests global restructuring plans employee benefits property plant equipment pensions postemployment goodwill benefits intangible assets equity compensation plans inventories leases accounts receivable earnings per share nonvoting marketable securities equity security cash cash equivalents statement cash flows noncurrent assets risk management current assets related parties accounts payable list subsidiaries associates noncurrent liabilities significant accounting policies report roche management internal control financial reporting statutory auditors report multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings statutory auditors report finance report financial review roche group financial review roche group results finance brief inside cover sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf covid pandemic outbreak posed unprecedented challenge healthcare systems across globe roche group responded challenge pharmaceuticals diagnostics businesses march diagnostics division launched cobas sarscov pcr test runs highvolume fully automated cobas cobas systems based pcr technology installed major hospitals laboratories around world roche diagnostics also continued complement portfolio pointofcare tests sarscov rapid antigen test pharmaceuticals division actemraroactemra adopted many countries treatment guidelines treat patients severe covid pneumonia august roche group announced partnering regeneron develop manufacture distribute investigational neutralising antibody combination roche groups business far proved largely resilient difficult environment pandemic nevertheless negative impact underlying business roche groups divisions various restrictions leading reduced hospitalisations outpatient visits impacted routine diagnostics testing led lower levels prescriptions many medicines notably require medical professional make infusions injections time major manufacturing supply chain issues far occurred groups planned drug launches filings pivotal phase iii trial readouts pivotal trial starts largely track indeed despite pandemic roche groups research development spending increased additionally various inlicensing transactions asset acquisitions led additions intangible assets chf billion pharmaceuticals division chf billion diagnostics division roche group reported sales growth constant exchange rates cer core operating profit growth ifrs net income increased due prior period including significant goodwill writeoffs core eps increased appreciation swiss franc almost currencies adverse impact results expressed swiss francs compared constant exchange rates percentage points sales percentage points core operating profit percentage points core eps pharmaceuticals division sales lower due biosimilar erosion especially pronounced us covid effects global uptake new medicines continued strong partly compensated effects diagnostics division sales covidrelated tests totalled chf billion drove increase divisional sales offset decline routine testing across portfolio roche group financial review finance report operating free cash flow chf billion decrease cer driven increased net working capital higher investments inlicensing alliance arrangements free cash flow chf billion lower reasons appreciation swiss franc significant negative impact free cash flows measures expressed chf terms group maintained sufficient liquidity support ongoing business activities well positioned meet financial obligations divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase extent covid pandemic negatively affected sales across whole business described following section impact covid pandemic sales pharmaceuticals division chf billion chf billion decrease cer driven biosimilar competition notably us pandemic due reduced hospitalisations outpatient visits growth new products additional sales actemraroactemra grew partly compensated declines new products major growth driver tecentriq hemlibra ocrevus perjeta kadcyla together contributing additional chf billion cer new sales tecentriq sales higher chf billion growth regions launch rollout hemlibra continued sales reaching chf billion sales ocrevus higher chf billion perjeta sales chf billion increase mostly due growth china kadcyla sales grew mainly due higher demand us europe us first biosimilar versions herceptin avastin mabtherarituxan entered market second half us sales three products chf billion cer lower europe first biosimilar versions avastin came market mid significant factor sales decline avastin second half diagnostics division reported sales chf billion increase cer sales various covidrelated tests chf billion cer excluding decline routine testing across portfolio various restrictions major growth area molecular diagnostics grew driven cobas sarscov pcr test centralised point care solutions sales decreased attributable reduction routine testing volumes covid pandemic partly offset sales sarscov rapid antigen test diabetes care sales decreased due continued overall contraction blood glucose monitoring market well covid effectsfinance report financial review roche group pharmaceuticals divisions core operating profit remained stable cer sales declined royalty operating income decreased chf billion due lower product disposal gains comparative period cost sales decreased due lower inventory writeoffs product mix factors productivity improvements lower collaboration profitsharing expenses marketing distribution costs decreased included activities support ongoing product launches rollouts notably tecentriq ocrevus perjeta cost decrease due reduced spending marketing activities partly attributable covid pandemic well lower personnel expenses research development costs grew oncology franchise remaining primary area activity growth spending mostly driven latestage investments ophthalmology personalised healthcare neuroscience also significant inlicensing transactions asset acquisitions bring external innovation roche group resulting intangible assets additions chf billion pharmaceuticals division diagnostics division core operating profit increased cer ahead sales growth cost sales grew due additional product volume higher shipping rates marketing distribution costs stable lower spending resulting covid restrictions cost containment measures offset higher personnel expenses inventory writeoffs research development costs increased due increased spending covid products development projects cardiac disease digital solutions ifrs operating profit increased cer pharmaceuticals division included chf billion income following release various litigation provisions ifrs operating profit increased chf billion diagnostics division prioryear figures including goodwill impairment charges chf billion relating diabetes care business results include chf billion amortisation impairment intangible assets chf billion expenses global restructuring plans operating free cash flow chf billion decrease cer due increase net working capital higher investments inlicensing alliance arrangements developments sales negative impact operating free cash flow pharmaceuticals division diagnostics division saw improvement cash generation free cash flow chf billion decrease cer due lower operating free cash flow expressed chf terms free cash flows measures show strong negative impact appreciation swiss franc financing costs decreased cer ifrs basis chf billion due early debt redemption losses chf billion lower interest expenses current year attributable early repayment debt second half groups effective core tax rate increased compared mainly due impact resolution several tax disputes reduced groups effective core tax rate percentage points percentage points net income increased cer ifrs basis chf billion core basis chf billion driven cases operating results amount net income attributable noncontrolling interests increased ifrs basis core basis due increased contribution chugai overall group results roche group financial review finance report income statement change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf see pages definition core results core epsfinance report financial review roche group impact covid pandemic roche medicines diagnostic tests tests detect virus march cobas sarscov pcr test detect active infection sarscov received us fda emergency use authorization became available markets accepting ce mark hospitals reference laboratories run test roche diagnostics highvolume fully automated cobas cobas systems based pcr technology installed major hospitals laboratories around world september sarscov rapid antigen test use pointofcare settings symptomatic asymptomatic people launched markets accepting ce mark test help healthcare professionals identify sarscov infection people suspected carry virus results typically ready minutes addition serves valuable initial screening test individuals exposed sarscovinfected patients highrisk environment september cobas sarscov influenza ab test use cobas systems received us fda emergency use authorization became available markets accepting ce mark test also available cobas liat systems pointofcare setting december highthroughput elecsys sarscov antigen test automated laboratory assay intended aid diagnosis active sarscov infection launched markets accepting ce mark filing also made us fda emergency use authorization tests detect immune response may elecsys antisarscov antibody test received us fda emergency use authorization became available markets accepting ce mark test designed help determine patient developed antibodies sarscov exposure virus tests run roche diagnostics cobas e analysers widely available around world september elecsys antisarscov antibody test launched markets accepting ce mark us fda emergency use authorization subsequently received immunology test targets antibodies spike protein used quantitatively measure antibodies people exposed sarscov play important part characterising vaccineinduced immune response sales various covidrelated tests chf billion cer sales cobas sarscov pcr tests combined covidrelated tests molecular diagnostics chf billion cer launch sarscov rapid antigen test late september combined related tests centralised point care solutions reached chf billion cer investigating treatment options actemraroactemra adopted many countries treatment guidelines treat patients severe covid pneumonia since march pharmaceuticals division initiated three global phase iii clinical trials investigating safety efficacy actemraroactemra tocilizumab covidassociated pneumonia results covacta empacta studies published submitted publication p eerreviewed journal uploaded data sharing platforms following initial interactions health authorities pharmaceuticals division continue monitor evolving clinical evidence actemraroactemra setting including combination antiviral remdesivir ongoing phase iii remdacta study addition trials independently led clinical trials multiple medicines including actemraroactemra taking place around world remapcap recovery trials uk time writing actemraroactemra approved clinical treatment covid pneumonia sales actemraroactemra chf billion increase compared increase partnerships collaborations august group announced partnering regeneron pharmaceuticals inc regeneron develop manufacture distribute casirivimab imdevimab investigational neutralising antibody combination addition investigated nonhospitalised patients casirivimab imdevimab currently studied phase iiiii clinical trial treatment covid hospitalised patients phase iii openlabel recovery trial hospitalised patients uk phase iii trial prevention covid household contacts infected individuals terms agreement regeneron distribute casirivimab imdevimab us roche group responsible distribution outside us november regeneron announced antibody combination received emergency use authorization us roche group financial review finance report october group announced also partnering atea pharmaceuticals inc atea develop manufacture distribute investigational novel oral antiviral phase ii study treatment hospitalised patients moderate covid ongoing phase ii outpatient setting started january addition may developed postexposure prophylactic settings december group announced partnership moderna inc moderna utilise elecsys antisarscov antibody test modernas mrna vaccine research trials facilitate quantitative measurement sarscov antibodies help establish correlation vaccineinduced protection levels antireceptor binding domain rbd antibodies impact roche groups business results revenues covid pandemic impact groups revenues absolute amounts phasing following factors affected sales across whole portfolio pharmaceuticals diagnostics businesses although impact varied product geography restrictions local travel public gatherings discouraged patients visiting physicians health practices hospitals especially affected elderly patients many hospitals health practices experienced certain level disruption leading delays cancellations patient visits especially noncritical procedures certain level forward purchasing first quarter doctors wrote prescriptions longer periods minimise patient visits pharmacies patients distributors stocked anticipation restrictions potential supply chain disruptions factors manifested higher level sales prior restrictions imposed followed lower level sales second quarter slow recovery beginning end second quarter restrictions progressively eased certain countries recovery continued third quarter year however reimposition restrictions many countries fourth quarter negative effect recovery quarterly development sales compared yearonyear growth cer q q q q full year pharmaceuticals division diagnostics division roche group pharmaceuticals division overall impact covid negative various restrictions leading reduced hospitalisations outpatient visits impacted routine diagnostic testing led lower levels prescriptions many medicines partly compensated additional sales actemraroactemra negative impacts strongest medicines regular visits health practices hospitals needed example infusions injections sales lucentis us ocrevus oncology portfolio therefore particularly affected although oncology portfolio also heavily impacted biosimilar erosion ongoing rollouts tecentriq hemlibra continued strongly although uptake hemlibra also impacted extent pandemic diagnostics division pandemic negative impact sales across whole portfolio compensated sales covidrelated tests notably cobas sarscov pcr test sarscov rapid antigen test pandemic led reduction overall diagnostic testing translated reduced instrument placements laboratory solutions business reduced sales reagents consumables delivery covidrelated tests led certain buildup inventories december notably recently launched sarscov rapid antigen test sales various covidrelated tests chf billion cer manufacturing supply despite supply logistics challenges due covid pandemic roche group able continue deliver medicines diagnostics wherever possible patients across broad range disease areas exceptional conditions date limited disruption group continually monitoring situation certain level volatility purchasing patterns noted significantly impacted supply chainfinance report financial review roche group announcement new clinical trials potential increase demand actemraroactemra pharmaceuticals division ramped manufacturing capacity increase globally available supply manufacturing investments also made relation partnership regeneron total additional capital expenditure related covidrelated projects pharmaceuticals division chf million roche group ensuring coordinated global overview additional supply requests provision medicines managed country level according local rules regulations close collaboration authorities diagnostics division ramped production capacity supply chain covidrelated testing products scaleup fast possible additional capital expenditure diagnostics division chf million roche group committed delivering many tests possible within limits supply delivering tests areas immediately effective tests shipped production sites locations appropriate infrastructure place testing begin without delay research development roche groups planned drug launches filings pivotal phase iii trial readouts pivotal trial starts largely track group continuously monitoring ongoing studies terms missed doses overall data integrity groups development teams taking significant efforts protect studies continued support health authorities ultimate impact also depend length severity pandemic pandemic prolonged duration launch new clinical trials progress ongoing clinical trials may delayed restrictions medical facilities patients deferring visits simply volunteering operating results major impact operating profit came abovementioned factors revenues overall operating expenses impacted extent covid pandemic various impacts partly offsetting additional costs incurred areas infrastructure distribution costs less spending travel congresses particular decline marketing distribution costs driven general slowdown marketing activities including lower travel costs reduced attendance congresses significant costs idle manufacturing capacity inventory writeoffs could attributed directly pandemic construction projects incurred minor costs delays restrictions core results group made changes core results concept result covid pandemic specific covidrelated impacts referred included ifrs core results noted core results exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets regardless cause liquidity financial position liquidity financial position roche group remained sound exceptional period liquidity group continues show strong cash generation ability free cash flow chf billion decrease cer free cash flow compared partly due investments inlicensing alliance arrangements resulted cash outflow chf billion roche continues enjoy strong longterm investmentgrade credit ratings aa standard poors aa moodys group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper program december debt drawn credit lines group renegotiate major contracts liquidity reasons group observe significant increase credit risk due covid pandemic bad debt expenses overdue receivables remained relatively low levels financial position december described previously significant bad debts writeoffs inventories could directly attributed covid factors intangible asset impairment charges chf billion incurred result delay clinical trials partly caused covid spark therapeutics haemophilia programme impairment issues noted goodwill intangible assets directly attributed pandemic impairment issues directly attributed pandemic noted financial assets although volatility global markets corresponding impact carrying value investments held fair value similarly certain volatility fair value pension assets discount rates first half situation largely stabilised end year exceptional funding payments groups pension plans currently foreseen roche group financial review finance report group results continued mergers acquisitions spark therapeutics december group acquired controlling interest spark therapeutics inc spark therapeutics publicly owned us company based philadelphia pennsylvania listed nasdaq stock market spark therapeutics fully integrated commercial company committed discovering developing delivering gene therapies spark therapeutics reported pharmaceuticals division cash purchase consideration usd billion equivalent chf billion annual financial statements allocation purchase price recorded balance sheet provisional first half identification valuation intangible assets assets liabilities completed accordingly provisional amounts recorded balance sheet december restated set note annual financial statements result values intangible assets increased chf billion deferred tax assets chf billion deferred tax liabilities chf billion consequent decrease goodwill chf billion asset acquisitions roche group acquired controlling interest promedior inc promedior inflazome ltd inflazome tmema ltd tmema lexent bio inc lexent bio pharmaceuticals division stratos genomics inc stratos genomics diagnostics division total initial cash consideration chf billion additional contingent payments may made based upon achievement performancerelated milestones chf billion related promedior asset acquisition group obtained rights promediors entire portfolio including phase iiiready asset prm recombinant human pentraxin molecule treatment idiopathic pulmonary fibrosis ipf chf billion related inflazome asset acquisition group obtained full rights inflazomes entire portfolio composed clinical preclinical orally available small molecule nlrp inhibitors transactions qualify business combinations ifrs accounted additions intangible assets cash flows business combinations asset acquisitions including settlement contingent consideration arrangements form part free cash flow details given note annual financial statements alliance transactions group completed licensing agreement sarepta therapeutics inc sarepta announced december group acquired exclusive rights launch commercialise srp sareptas investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside us initial payments resulted recognition chf billion intangible assets chf billion equity investments july group announced collaboration blueprint medicines corporation blueprint medicines codevelopment cocommercialisation rights pralsetinib gavreto investigational precision therapy latestage development people retaltered nonsmall cell lung cancer nsclc various types thyroid cancer solid tumours terms agreement group made initial payments chf billion chf billion recognised intangible assets chf billion equity investment parties cocommercialise pralsetinib us group responsible commercial activities outside us gavreto approved us treatment adults metastatic retfusionpositive nsclc september treatment people advanced metastatic retmutant retfusionpositive thyroid cancers december august group entered licensing agreement regeneron pharmaceuticals inc regeneron parties collaborate developing manufacturing regenerons investigational covid antibody combination casirivimab imdevimab latestage clinical trials treatment prevention sarscov infection terms agreement company committed dedicate certain manufacturing capacity casirivimab imdevimab year regeneron distribute casirivimab imdevimab us group responsible distribution outside us initial payments november regeneron announced antibody combination casirivimab imdevimab received emergency use authorization usfinance report financial review roche group october group entered licensing agreement atea pharmaceuticals inc atea parties codevelop ateas orally administered directacting small molecule antiviral covid patients initial payment chf billion recognised intangible asset approved atea distribute us option request groups support group responsible global manufacturing distribution outside us significant transactions included upfront payment chf billion arrakis therapeutics strategic collaboration licensing agreement discovery rnatargeted small molecule rsm drugs broad set targets across pharmaceutical divisions research development areas also upfront payment chf billion vaccibody worldwide collaboration licensing agreement develop dnabased individualised neoantigen cancer vaccines based vbneo across multiple tumour types addition also upfront payment chf billion vividion therapeutics rights vividions proteomics screening platform proprietary small molecule library target novel e ligases well range oncology immunology therapeutic targets upfront payment chf billion ucb rights ucbs investigational monoclonal antibody drug developed potential treatment patients alzheimers disease total inlicensing alliance transactions completed resulted intangible assets chf billion recognised chf billion total cash outflow chf billion included sarepta blueprint medicines equity investments well payment chf billion relating dicerna pharmaceuticals transaction treatments chronic hepatitis b virus infection total amount chf billion included pharmaceuticals divisions operating free cash flow chf billion diagnostics divisions operating free cash flow chf billion sarepta blueprint medicines equity investments included free cash flow treasury activities transactions additional payments may made based upon achievement performancerelated milestones profitsharing royalty arrangements global restructuring plans group continued implementation various global restructuring plans initiated prior years global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche group financial review finance report diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated costs site consolidation employeerelated costs mainly optimisation enabling functions within drug product network site closure costs included impairment reversal chf million global restructuring plans major items included employeerelated costs chf million mainly outsourcing operational activities global shared service centres external providers well driving business transformation efficiency gains total global restructuring costs chf billion details given note annual financial statements impairment goodwill intangible assets pharmaceuticals division pharmaceuticals division recorded impairment charges intangible assets chf billion major part impairment charge chf billion coming partial impairment intangible asset spk novel gene therapy treatment haemophilia acquired part spark therapeutics acquisition impairment result delay clinical trials partly impacted covid pandemic leading reduced sales expectations addition charge chf billion related partial impairment product intangible asset luxturna marketed gene therapy treatment patients inherited retinal disease due mutations copies rpe gene acquired part spark therapeutics acquisition impairment result reduced sales expectations diagnostics division impairment charges chf billion relating goodwill avl medical instruments geneweave acquisitions detailed note annual financial statements impairments intangible assets diagnostics division impairment charges chf billion pharmaceuticals division diagnostics division recorded impairment charges chf billion major part charge chf billion partial writeoff goodwill related diabetes care business details given notes annual financial statements legal environmental cases based development various litigations notably accutane case us provisions previously held released resulted income chf billion significant developments affecting financial results details given note annual financial statements net income earnings per share ifrs net income increased chf terms cer core eps increased cer decreased chf core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets mergers acquisitions alliance arrangements amount net income attributable noncontrolling interests increased ifrs basis core basis due increased contribution chugai overall group resultsfinance report financial review roche group net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring plans intangible asset amortisation goodwill intangible asset impairment mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect swiss tax reform normalisation equity compensation plan tax benefit core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt lease liabilities pensions income taxes nonoperating assets net total net assets provisional balance sheet amounts restated final accounting spark therapeutics acquisition see note annual financial statements compared start year swiss franc appreciated almost currencies us dollar strong effect additionally japanese yen brazilian real significant effect groups net operating assets negative translation impact partly offset group level natural hedge groups us dollardenominated debt exchange rates used given roche group financial review finance report net working capital increased significantly divisions pharmaceuticals division inventories increased driven active management ensure product availability launch supply net liability position receivablespayables decreased due settlement accruals recorded end diagnostics division inventories increased due ongoing rollout covidrelated products notably recently launched sarscov rapid antigen test trade receivables increased due sales growth overall longterm net operating assets increased due inlicensing alliance arrangements also due asset acquisitions added chf billion pharmaceuticals division chf billion diagnostics division intangible assets partly offset impairments goodwill intangible assets decrease net debt driven free cash flow chf billion offset annual dividend payments chf billion outflows transactions equity instruments chf billion net pension liability higher following decrease discount rates regions net tax assets increased mainly due taxes paid exceeding income tax expenses deferred tax effects pension plans lease liabilities chf billion increased mainly due additional office space rented flatiron health free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid free cash flow see pages definition free cash flow detailed breakdown groups operating free cash flow chf billion decrease cer due increased net working capital higher investments inlicensing alliance arrangements pharmaceuticals division lower sales increased research development spending negative impact operating free cash flow partly offset lower spending marketing distribution diagnostics division sales growth positive impact operating free cash flow free cash flow chf billion decrease cer due lower operating free cash flow higher financial longterm investments partly offset lower interest paid lower taxes paidfinance report financial review roche group pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets c net operating assets c free cash flow b operating free cash flow margin sales see pages definition core results b see pages definition free cash flow c provisional balance sheet amounts restated final accounting spark therapeutics acquisition see note annual financial statements roche group financial review finance report sales overview pharmaceuticals division sales therapeutic area change sales sales chf chf cer oncology immunology neuroscience haemophilia ophthalmology infectious diseases therapeutic areas total sales biosimilar competition covid pandemic overall negative impact divisions sales general dampening sales covidrelated restrictions beginning second quarter hospitalisations outpatient visits decreased particularly impacted sales ocrevus hemlibra lucentis mabtherarituxan new product sales continued partly compensate increasing competition biosimilars notably mabtherarituxan herceptin avastin us covid impacts actemraroactemra sales increased driven adoption treatment guidelines patients severe covid pneumonia sales growth new products driven continuing rollout tecentriq hemlibra ocrevus perjeta kadcyla together contributed additional chf billion cer new sales tecentriq sales grew chf billion mostly due higher demand us major eu markets launch rollout hemlibra continued across us japan major eu markets sales reaching chf billion increase ocrevus continued growth development sales increase chf billion sales uptake ocrevus hemlibra especially adversely affected covid pandemic perjeta sales china major driver growth kadcyla sales grew mainly due higher demand us europe patients switched new standard care following positive readout katherine study october biosimilar competition negative impact continuing erosion herceptin mabtherarituxan avastin mostly us global sales three products fell chf billion cer total sales chf billion decrease covid pandemic also impact sales three products notably china mabtherarituxan us sales china also affected following price updates since inclusion national reimbursement drug list nrdl first biosimilar versions herceptin avastin mabtherarituxan entered market us second half combined us sales three products chf billion cer lower sales herceptin mabtherarituxan europe declined chf billion cer sales avastin europe declined chf billion cer second half since first biosimilar version avastin entered market sales oncology therapeutic area decreased due biosimilar competition herceptin avastin mabtherarituxan described partially compensated growth tecentriq perjeta tecentriq sales grew regions mostly due higher demand us major eu markets rollout japan perjeta sales increased mostly due growth china kadcyla alecensa showed continuing postlaunch growth across regions sales immunology grew actemraroactemra xolair increasing respectively increase actemraroactemra sales mainly driven adoption medicine many countries guidelines treat patients severe covid pneumonia mabtherarituxan sales immunology decreased driven us due impacts covid pandemic biosimilar entry lucentis sales declined us affected covid restrictions disrupting ophthalmology practices limiting patient access infectious diseases sales lower due lower sales tamiflu rocephinfinance report financial review roche group product sales pharmaceuticals division sales change sales sales chf chf cer oncology avastin perjeta herceptin mabtherarituxan tecentriq kadcyla alecensa gazyvagazyvaro xeloda polivy tarceva others total oncology immunology actemraroactemra xolair esbriet mabtherarituxan pulmozyme cellcept others total immunology neuroscience ocrevus madopar others total neuroscience haemophilia hemlibra total haemophilia ophthalmology lucentis total ophthalmology infectious diseases tamiflu rocephin others total infectious diseases therapeutic areas activasetnkase mircera neorecormonepogin others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology therapeutic areas roche group financial review finance report avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma liver cancer combination tecentriq avastin regional sales change sales sales chf chf cer united states europe japan international total sales us sales decreased due launch biosimilars europe sales decrease due biosimilar competition second half year competitive pressure notably germany france italy japan sales decreased due government price cut biosimilar competition international region main driver sales decline canada ocrevus relapsing forms multiple sclerosis rms primary progressive multiple sclerosis ppms ocrevus regional sales change sales sales chf chf cer united states europe international total sales continuously growing demand indications us growth driven new returning patients higher proportion sales coming returning patients europe international region ocrevus continues show strong uptake launched notably france germany canada spain sales ocrevus impacted covid treatment administered intravenous infusion requires hospital visits many cases cancelled delayed pandemic restrictions mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl pemphigus vulgaris pv rheumatoid arthritis ra well certain types antineutrophil cytoplasmic antibody ancaassociated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales lower due biosimilar erosion well market contraction covid pandemic restrictions us sales decreased decline oncology immunology segments part driven covid sales international region lower decline china following price updates since inclusion national reimbursement drug list nrdl decline brazil japan sales decreased due biosimilar competitionfinance report financial review roche group franchise herceptin perjeta kadcyla phesgo herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sales change sales sales chf chf cer united states europe japan international total sales perjeta regional sales change sales sales chf chf cer united states europe japan international total sales kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales phesgo regional sales change sales sales chf chf cer united states total sales sales franchise decreased chf billion herceptin sales lower driven biosimilar launches started second half us mid japan europe sales perjeta grew increases mostly driven china early breast cancer metastatic breast cancer settings us sales perjeta grew due growth early breast cancer setting partly offset covid restrictions kadcyla sales increased notably early breast cancer setting kadcyla sales benefited positive readout katherine study patients switching new standard care roche group financial review finance report actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth driven adoption actemraroactemra many countries treatment guidelines treat patients severe covid pneumonia us major contributor sales increase along russia india spain various clinical studies covacta empacta evaluate safety efficacy actemraroactemra patients severe covid pneumonia carried results made available healthcare authorities tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc extensivestage small cell lung cancer pdlpositive triplenegative breast cancer unresectable metastatic hepatocellular carcinoma tecentriq regional sales change sales sales chf chf cer united states europe japan international total sales sales grew growth regions notably us higher sales driven new indications extensivestage small cell lung cancer pdlpositive triplenegative breast cancer unresectable metastatic hepatocellular carcinoma europe sales grew mainly driven germany hemlibra haemophilia hemlibra regional sales change sales sales chf chf cer united states europe japan international total sales global rollout hemlibra continued throughout sales continued show strong uptake especially us europe strong demand noninhibitor segment covid restrictions caused slowdown growth due missed patient visits affecting potential new patients whereas existing patients remained treatmentfinance report financial review roche group xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sales change sales sales chf chf cer united states total sales sales increased driven indications xolair remains market leader larger allergic asthma indication lucentis wet agerelated macular degeneration wamd macular oedema following retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sales change sales sales chf chf cer united states total sales us sales decreased approved indications covid pandemic caused disruption hospitals ophthalmology practices many patients delayed treatment restrictions activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sales change sales sales chf chf cer united states international total sales sales higher increased demand tnkase covid pandemic due injection administration method easier use alecensa alkpositive nonsmall cell lung cancer nsclc alecensa regional sales change sales sales chf chf cer united states europe japan international total sales global uptake continued increase sales across regions international main growth driver china sales benefitted nrdl listing roche group financial review finance report esbriet idiopathic pulmonary fibrosis ipf esbriet regional sales change sales sales chf chf cer united states europe international total sales sales grew driven increased use us indications ipf pharmaceuticals division sales region change sales sales chf chf cer united states europe japan international total sales united states sales decreased driven combined fall herceptin avastin mabtherarituxan sales due launches biosimilars well market contractions due covid particularly mabtherarituxan hemlibra continued show strong uptake since launched november actemraroactemra sales increased mostly due use hospitalised patients severe covid pneumonia tecentriq sales increased due growth new indications ocrevus sales increased driven new returning patient demand partly dampened covid effects sales franchise decreased driven lower herceptin sales partially offset sales increase kadcyla notably early breast cancer setting lucentis sales decreased due covid impacts europe sales grew new product sales compensating biosimilar competition herceptin mabtherarituxan avastin impacts covid pandemic tecentriq sales continued grow increased following successful launches notably germany continued uptake across europe hemlibra ocrevus showed strong uptake particular france germany japan sales decreased driven lower sales avastin herceptin mabtherarituxan negatively affected biosimilar competition government price cuts decline partially compensated recently launched products including tecentriq hemlibra perjeta grew due launch additional indication early breast cancer international sales increased mostly driven china russia strong uptake china perjeta alecensa partially offset nrdl price update covid impacts sales increase china due base effect reduction level channel inventory sales rest international region increased growth new products perjeta ocrevus tecentriq hemlibra kadcyla alecensa actemraroactemra offsetting decline herceptin mabtherarituxan sales russia grew due inclusion tecentriq kadcyla perjeta herceptin national oncology program adoption actemraroactemra countrys covid treatment guidelines well launches hemlibra ocrevusfinance report financial review roche group pharmaceuticals division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales competition generic medicines biosimilars groups pharmaceutical products generally protected patent rights intended provide group exclusive marketing rights various countries however patent rights varying scope duration group may required enter costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars non comparable biologics reasons could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically results significant reduction net sales relevant product manufacturers typically offer versions lower prices patents expiry always integral part groups business model future growth remain driven innovation latest information clinical studies included annual report details groups product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm intellectual property biologics involve multiple patents patent timelines individual product therefore difficult give exact date patent expiry biologic medicines groups basic primary patents mabtherarituxan herceptin avastin expired us eu secondary patent rights subcutaneous formulations mabtherarituxan herceptin expire beyond addition recent approaching patent expiries us lucentis may impact sales product biosimilar competition mabtherarituxan herceptin avastin us europe japan estimated negative impact chf billion cer main impact sales us fell chf billion cer covid pandemic negative impact overall market notably mabtherarituxan us united states first biosimilar versions herceptin avastin launched us mid first biosimilar versions mabtherarituxan late sales three products chf billion lower cer prior period decline us sales three products also affected covid pandemic certain impact overall market particularly mabtherarituxan europe first biosimilar versions mabtherarituxan herceptin launched europe mid mid respectively marketed eu countries major factor continuing sales decline chf billion cer two products europe first biosimilar versions avastin came market europe mid significant factor decline sales chf billion cer avastin europe second half japan japan first biosimilar versions mabtherarituxan herceptin launched sales impacted government price cuts biosimilar versions avastin launched late colorectal cancer indication nonsmall cell lung cancer indication sales three products combined lower impacted competition government price cuts roche group financial review finance report product sales affected biosimilar launches change chf chf cer comment mabtherarituxan us first biosimilar launches late herceptin us first biosimilar launches mid avastin us first biosimilar launches mid mabtherarituxan europe first biosimilar launches mid herceptin europe first biosimilar launches mid avastin europe first biosimilar launches mid mabtherarituxan japan first biosimilar launches early herceptin japan first biosimilar launches mid avastin japan first biosimilar launches late colorectal nonsmall cell lung cancer indications sales mabtherarituxan herceptin avastin disclosed previous sections including regional breakdowns summarised table noted previous sections yearonyear movements also driven regular price volume changes well impacts covid pandemic biosimilar competition one factor overall picture total mabtherarituxan herceptin avastin sales change division sales division sales chf chf cer united states europe japan international total sales operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income decreased cer royalty income increased settlement gain chf million compensated lower income expired cabilly patent royalty income venclexta venclyxto sales outside us increased royalty income lucentis sales outside us lower decrease utlicensing income due lower milestone income income product disposals decreased due income chf million sale rights lexotan bactrim dormicum partially compensated income chf million sale global rights rocaltrol excluding china japan valium well higher profitshare income due increased sales venclextavenclyxto usfinance report financial review roche group pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs decreased cer percentage sales cost sales decreased percentage points manufacturing cost sales decreased sales declined due inventory writeoffs product mix factors productivity improvements royalty expenses lower decrease royalty expenses related expired cabilly patent partially offset increased sales certain royaltybearing products notably ocrevus collaboration profitsharing expenses decreased driven lower us sales mabtherarituxan impairment property plant equipment idle plant recognised restructuring costs mainly related resourcing flexibility initiatives amortisation charges went due rozlytrek product intangible assets started amortised product launch second half luxturna product intangible assets spark therapeutics acquisition impairment charges relate luxturna due reduced sales expectations pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs decreased cer percentage sales decreased comparative period major marketing distribution activities included supporting rollouts tecentriq ocrevus perjeta supporting launch activities cost decrease mainly due general slowdown marketing activities including lower expenses congresses due covid restrictions cost decrease also associated lower personnel expenses including lower headcount costs field force restructuring costs related transformation initiatives pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales increased percentage points oncology franchise remained primary area research development cancer immunotherapy portfolio key driver neuroscience immunology also represent significant areas spending growth spend mostly driven latestage investments ophthalmology personalised healthcare neuroscience well spending spark therapeutics flatiron health amortisation charges higher notably due exercise priority review voucher impairment charges mainly result delay clinical trials spark therapeutics haemophilia intangible asset roche group financial review finance report addition pharmaceuticals division acquired various product intangibles development technologies inlicensing transactions asset acquisitions total added chf billion intangible assets major items payments chf billion sarepta exclusive right launch commercialise srp sareptas investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside us chf billion blueprint medicines part licensing collaboration agreement group obtained codevelopment cocommercialisation rights pralsetinib gavreto blueprint medicines investigational precision therapy latestage development people retaltered nonsmall cell lung cancer nsclc various types thyroid cancer solid tumours investments include payments chf billion atea chf billion inflazome asset acquisition chf billion promedior asset acquisition see sections mergers acquisitions alliance transactions details pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment rightofuse assets business taxes capital taxes general items general administration core basis global restructuring plans mergers acquisitions alliance transactions legal environmental cases pensions plan settlements total ifrs basis core costs increased cer percentage sales increased administration costs higher mainly due recently acquired spark therapeutics also flatiron health foundation medicine business taxes capital taxes increased primarily due relatively lower costs us branded prescription drug fee general items increased due lower personnel costs restructuring costs related business transformation initiatives income legal environmental cases related release accutane us litigation provision roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals chugai pharmaceuticals division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales external customers pharmaceuticals division total core operating profit operating profit include elimination chf minus million unrealised intercompany gains roche pharmaceuticals chugai chf minus million cer reported japanese yen sales chugai external customers decreased sales within division increased chugai core operating profit increased due higher royalty income roche pharmaceuticals well higher gross profit sales within division partially offset higher research development costs operating free cash flow chugai increased cer mainly result strong operating performance partially offset increase net working capital appreciation swiss franc japanese yen adverse impact approximately percentage points chugai core operating profit groups consolidated results expressed swiss francsfinance report financial review roche group financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets provisional balance sheet amounts restated final accounting spark therapeutics acquisition see note annual financial statements absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc appreciated almost currencies us dollar strong effect additionally japanese yen brazilian real significant effect net operating assets pharmaceuticals division resulted net negative translation impact exchange rates used given net working capital net working capital increased net trade working capital higher inventory higher driven active management ensure product availability launch supply trade receivables increased compared start year increase due temporarily extended payment terms us noted interim results june settled second half net liability position receivables payables decreased following settlement accruals recorded end longterm net operating assets overall longterm net operating assets increased due increased intangible assets lower provisions intangible asset additions inlicensing transactions asset acquisitions pharmaceuticals division chf billion include chf billion paid sarepta exclusive rights launch commercialise sareptas investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside us furthermore roche paid chf billion blueprint medicines codevelopment cocommercialisation rights pralsetinib gavreto investigational precision therapy latestage development people retaltered nonsmall cell lung cancer nsclc various types thyroid cancer solid tumours additional intangible assets purchases asset acquisitions inflazome promedior upfront payments atea arrakis therapeutics vaccibody vividion therapeutics ucb see section alliance transactions capital expenditure includes manufacturing investments us japan switzerland germany site developments switzerland us chugais research facilities yokohama japan total additional capital expenditure covidrelated projects pharmaceuticals division chf million provisions decreased due release accutane us litigation provision cash settlement past royalties related pdl inhibitor litigation roche group financial review finance report free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales see pages definition free cash flow detailed breakdown pharmaceuticals divisions operating free cash flow decreased cer chf billion cash generation business measured operating profit net operating cash adjustments lower sales increased research development spending negative impact operating free cash flow partly offset lower spending marketing distribution net working capital absorbed additional chf billion cash largely driven higher inventory settlement payables reasons described financial position section capital expenditure higher prior year part due response covid pandemic investments intangible assets significantly higher include payments sarepta chf billion blueprint medicines chf billion new inlicensing alliance transactions atea arrakis therapeutics vaccibody vividion therapeutics ucb well payment dicerna pharmaceuticals transaction see section alliance transactions appreciation swiss franc significant negative impact free cash flows measures expressed chf termsfinance report financial review roche group diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow b operating free cash flow margin sales see pages definition core results b see pages definition free cash flow sales overview diagnostics division sales business area change sales sales chf chf cer centralised point care solutions molecular diagnostics diabetes care tissue diagnostics total sales diagnostics division reported overall sales growth cer chf billion covid pandemic contrasting impacts different parts business molecular diagnostics reported sales growth due launch cobas sarscov pcr test centralised point care solutions sales decreased due reduction routine testing volume partially offset launch covid testing products second half diabetes care sales declined due continued overall contraction blood glucose monitoring market impact covid pandemic roche group financial review finance report sales various covidrelated tests chf billion cer offsetting decline routine testing driving diagnostics division annual growth sales covidrelated tests molecular diagnostics chf billion cer consisting mainly cobas sarscov pcr tests launched march remaining chf billion cer covidrelated test sales centralised point care solutions mostly sarscov rapid antigen test launched september centralised point care solutions regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales overall sales decreased due combined effects healthcare centres deprioritising routine care allocate resources covid preparedness efforts patients avoiding healthcare centres fear exposure covid emea decline routine testing business compensated sales growth pointofcare covid testing products north america decline offset custombiotech business rest world sales lower notably china lower immunodiagnostic reagent sales compensated pointofcare covid testing sales molecular diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales overall sales rose sales growth driven launch cobas sarscov pcr test march cobas sarscov influenza ab test september instrument sales increased installed base end units highthroughput cobas systems diabetes care regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales sales decreased line continued contracting blood glucose monitoring market due patients switching continuous glucose monitoring systems covid pandemic also impact decrease reflected mainly emea region decline notably germany italy uk tissue diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales sales increased due growth advanced staining instruments sales recovery manufacturing delays prior year north america well increased sales companion diagnostics sales partially offset lower testing volume due covid pandemic mostly north america regionally asiapacific grew due higher reagent salesfinance report financial review roche group diagnostics division sales region change sales sales chf chf cer europe middle east africa emea north america asiapacific latin america japan total sales molecular diagnostics global driver sales growth mainly north america emea offsetting reductions routine testing business rest portfolio furthermore sales emea positively impacted centralised point care solutions business due sales sarscov rapid antigen test allowing fast triage decisions point care sales decrease asiapacific driven china due decrease routine testing following covid pandemic restrictions diagnostics division continued reduce channel inventory china diagnostics division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis core royalties operating income decreased cer driven base effect settlement royalty dispute due lower royalty income following lower immunodiagnostics sales partner companies roche group financial review finance report diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer due higher sales increased costs global supply chain due additional product volume higher shipping rates increase sales growth due favourable product mix core costofsales ratio decreased percentage points global restructuring costs related strategy plans impairment charges related intangible assets molecular diagnostics sequencing businesses diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs remained stable cer due lower spending congresses travelling following covid restrictions well cost containment measures offset higher personnel expenses inventory writeoffs core basis marketing distribution costs percentage sales decreased compared global restructuring costs decreased due significant projects related sales force prior year diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer due spending covid products development projects cardiac disease within centralised point care solutions portfolio well increased spending digital solutions percentage sales research development core costs stable global restructuring costs decreased due costs strategy plans previous yearfinance report financial review roche group diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment rightofuse assets gains losses disposal divestment subsidiaries business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases total ifrs basis core costs increased cer percentage sales core costs decreased administration costs higher due legal expenses us global restructuring plan costs relate mainly employee expenses strategy plans impairment charges chf million due goodwill impairment related avl medical instruments geneweave acquisitions mergers acquisitions alliance transactions included income reversal contingent consideration provisions legal environmental costs included litigation costs meso case financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given roche group financial review finance report currency translation effects balance sheet amounts compared start year swiss franc appreciated almost currencies us dollar strong effect additionally brazilian real turkish lira significant effect net operating assets diagnostics division resulted negative translation impact exchange rates used given net working capital net working capital increased due higher inventories trade receivables partially offset higher net liability receivablespayables inventory increased due ongoing rollout covidrelated products including recently launched sarscov rapid antigen test increase trade receivables due sales growth increase net liability receivablespayables came higher product accruals employeerelated accruals longterm net operating assets overall longterm net operating assets increased cer mainly attributable increase property plant equipment site investments germany us switzerland included covidrelated manufacturing expansion chf million intangible assets lower due goodwill impairment relating avl medical instruments geneweave acquisitions partly offset intangible asset additions inlicensing transactions asset acquisitions diagnostics division chf billion mainly stratos genomics asset acquisition free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales definition free cash flow detailed breakdown see pages operating free cash flow diagnostics division chf billion increase compared cash generation business measured operating profit net operating cash adjustments increased chf million sales growth positive impact operating free cash flow net working capital increased absorbed chf million cash attributable increases inventories receivables offset higher payables accruals reasons described financial position section capital expenditure slightly higher due site investments decline investments intangible assets related inlicensing transaction appreciation swiss franc significant negative impact free cash flows measures expressed chf termsfinance report financial review roche group corporate operating results corporate operating results summary change chf chf cer administration business taxes capital taxes general items general administration costs core basis global restructuring plans legal environmental cases total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow b operating free cash flow see pages definition core results b see pages definition free cash flow detailed breakdown general administration costs increased cer core basis administration costs also higher increase due buildup shared service centre network provides services divisions total costs ifrs basis affected lower level restructuring activities corporate functions corporate operating free cash flow showed higher outflow due higher administration costs settlement payables roche group financial review finance report foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy results expressed swiss francs negatively impacted appreciation swiss franc almost currencies impact expressed swiss francs compared constant exchange rates percentage points sales percentage points core operating profit percentage points core eps sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact increase average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro cost sales marketing administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yenfinance report financial review roche group treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position net debt lease liabilities pensions income taxes c equity investments derivatives net collateral net interest payable nonoperating assets net total net assets liabilities c free cash flow b treasury activities taxes paid total see pages definition core results b see pages definition free cash flow c provisional balance sheet amounts restated final accounting spark therapeutics acquisition see note annual financial statements financing costs core financing costs chf million decrease cer compared interest expenses debt decreased cer chf million mainly due early repayment debt second half losses early debt redemption chf million net interest cost defined benefit pension plans decreased cer due lower discount rates germany us end full analysis financing costs given note annual financial statements roche group financial review finance report financial income expense core financial income expense net expense chf million compared net income chf million income equity securities predominantly reflects fair value changes realised gains losses roche venture fund investments notably investment allakos reported net gain chf million compared net gain chf million net interest income decreased cer chf million due lower liquid funds levels available investments lower interest rates compared net foreign exchange results reflect hedging costs losses unhedged positions losses chf million compared net losses chf million full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate increased percentage points mainly due impact resolution several tax disputes reduced groups effective core tax rate percentage points percentage points ifrs results saw effective tax rate increase percentage points addition core impacts mentioned noncore impacts swiss tax reform impairments goodwill tax deductible also impacted ifrs tax rate ifrs results also include releases contingent consideration provisions taxable hence net effect mergers acquisitions alliance transactions line table details groups income tax expenses related balance sheet positions given note annual financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect swiss tax reform normalisation equity compensation plan tax benefit groups effective tax rate ifrs basis financial position decrease net debt driven free cash flow chf billion offset annual dividend payments chf billion outflows transactions equity instruments chf billion net pension liability higher due decrease discount rates regions net tax assets increased mainly due taxes paid exceeding income tax expenses deferred tax effects pension plans december group held equity investments market value chf billion consist mostly holdings biotechnology pharmaceuticals companies acquired part licensing transactions scientific collaborations investments roche venture fund free cash flow net cash outflow treasury activities remained stable chf billion lower interest payments offset investments financial longterm assets notably chf billion equity sarepta total taxes paid decreased chf billion line lower pretax profitsfinance report financial review roche group cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow treasury activities taxes paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages operating free cash flow decreased cer chf billion lower chf terms due increased net working capital delivery covidrelated tests led certain buildup inventories december also higher investments inlicensing alliance arrangements pharmaceuticals division lower sales increased research development spending negative impact operating free cash flow partly offset lower spending marketing distribution diagnostics division sales growth positive impact operating free cash flow free cash flow chf billion lower cer lower chf result lower operating free cash flow higher financial longterm investments partly offset lower interest paid lower taxes paid appreciation swiss franc significant negative impact free cash flows measures expressed chf terms roche group financial review finance report net debt millions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow dividend payments transactions equity instruments mergers acquisitions net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period definition net debt see net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes net debt position group december chf billion decrease chf billion december driven free cash flow chf billion offset annual dividend payments chf billion outflows transactions equity instruments chf billion transactions equity instruments relate purchases connection groups equity compensation plansfinance report financial review roche group contractual obligations commitments group obligations commitments set table carrying values shown consolidated balance sheet potential obligations shown discounted riskadjusted unless otherwise noted amounts denominated foreign currencies translated swiss francs december exchange rates provisions legal environmental matters included timing amount cash outflow uncertain contingent development matters question contractual obligations commitments december millions chf potential obligation undiscounted less carrying year years years years total value onbalance sheet debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities unfunded defined benefit plans total onbalance sheet commitments offbalance sheet capital commitments property plant equipment leasing commitments contract manufacturing commitments alliance collaboration commitments total offbalance sheet commitments total contractual commitments references notes annual financial statements debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments contingent consideration potential payments arising mergers acquisitions carrying values riskadjusted discounted lease liabilities future obligations noncancellable lease contracts unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations carrying values discounted future company contributions groups funded plans shown table capital commitments property plant equipment noncancellable commitments purchase construction mainly roche sites basel switzerland south san francisco us mannheim germany also chugai research development site yokohama japan leasing commitments major noncancellable commitments signed lease agreements lease term yet started mainly relate foundation medicines site boston us roche group financial review finance report contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising groups major longterm agreements external contract manufacturing organisations cmos alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing alliance arrangements intangible asset purchase agreements including asset acquisitions potential payments alliance partners asset purchase agreements within next three years included assuming projects currently development successful potential payments beyond three years included asset purchase agreements pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources expenses groups defined benefit plans chf million chf million defined benefit plans funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans increased compared start year came increase fair value plan assets partly offset higher defined benefit obligation due decrease discount rates regions funding status pension funds monitored local pension fund governance bodies well closely reviewed group level total cash outflow groups defined benefit plans chf billion compared chf billion higher additional contributions paid groups pension plans japan unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations unfunded liabilities plans increased due decrease eurozone discount rate full details groups pensions postemployment benefits given note annual financial statementsfinance report financial review roche group roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer year high volatility stock markets equity markets recovered heavy losses first quarter swiss market index smi stayed stable outperforming european indices trailing major us indices global healthcare sector grew roche outperformed peers chf terms strong sales growth diagnostics launches new products peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source refinitiv eikon data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche group financial review finance report proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting would th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security also information roche securities given pages information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per sharefinance report financial review roche group debt scheduled debt repayments debt redemptions new debt issued maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf b beyond total total translated december exchange rates b proceeds bonds notes eur million swapped us dollars therefore consolidated results bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations full year free cash flow chf billion included cash generated operations well payment interest tax shortterm financing requirements group commercial paper program us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines december commercial paper notes totalling usd billion outstanding usd billion longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors aa moodys facilitate efficient access international capital markets information groups debt given note annual financial statements roche group financial review finance report financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt repayment liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables chf billion since beginning financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries decrease compared december euro terms group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions since groups trade receivables balance southern europe decreased euro terms liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors aa moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper program december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var decreased since december reflecting reduction us interest rates interest rate risk interest rate risk arises movements interest rates could affect groups financial result value group equity group may use interest rate derivatives manage interest raterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statementsfinance report financial review roche group international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since new revised standards applied group implemented various minor amendments existing standards interpretations material impact groups overall results financial position amendments ifrs business combinations definition business mandatorily applicable early adopted group roche group roche group consolidated financial statements finance report roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statements finance report roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income oci remeasurements defined benefit plans fair value changes equity investments fair value oci items never reclassified income statement fair value changes debt securities fair value oci cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment rightofuse assets goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity disclosed note balance sheet december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published balance sheet provided note disclosed note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative balance sheet december restated roche group roche group consolidated financial statements finance report roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations asset acquisitions divestment subsidiaries interest dividends received sales equity securities debt securities purchases equity securities debt securities sales purchases money market instruments time accounts three months net investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements changes ownership interest subsidiaries equity contribution noncontrolling interests interest paid principal portion lease liabilities paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january implementation ifrs leases january revised net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december year ended december january net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december disclosed note group changed accounting policies leases following implementation ifrs leases effective january details additional assets liabilities reported effective january provided note roche group notes roche group consolidated financial statements finance report notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors february subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist various performance obligations satisfied different times contracts entered diagnostics division typically include performance obligations instruments including provided leasing arrangements reagents consumables services instruments may sold cash sales transactions discounted prices instruments provided operating lease arrangements entire lease revenue may variable subject subsequent reagents sales sales net discounts based estimates regarding related obligations including standalone selling prices requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments licensing fees reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs revenues contracts customers straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating us pharmaceuticals business amounted chf million chf million associated expected sales returns estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustmentfinance report notes roche group consolidated financial statements roche group business combinations group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest consideration transferred business combination management judgement particularly involved assessment whether net assets acquired constitute business recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms management also applies considers appropriate optional concentration test set ifrs business combinations aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets impairment property plant equipment rightofuse assets goodwill intangible assets december group chf million property plant equipment see note chf million rightofuse assets see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment rightofuse assets intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lowerthananticipated product sales could lead shorter useful lives impairment impairment financial assets december group chf million allowance doubtful accounts trade lease receivables see note allowance doubtful accounts based assumptions risk default expected loss rates group uses judgement making assumptions selecting inputs calculation allowance doubtful accounts based companys past experience existing market conditions well forwardlooking estimates end reporting period pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter lifespans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated reliable estimate made provision recorded contingent liabilities disclosed material december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements business combinations could chf million see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops roche group notes roche group consolidated financial statements finance report income taxes december group current income tax net liability chf million deferred tax net asset chf million see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations tax positions uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases group lessee key judgements include assessing whether arrangements contain lease determining lease term assess whether contract contains lease requires judgement whether depends specified asset whether group obtains substantially economic benefits use asset whether group right direct use asset order determine lease term judgement required extension termination options assessed along facts circumstances may create economic incentive exercise extension option exercise termination option estimates include calculating discount rate based incremental borrowing rate december group chf million rightofuse assets chf million lease liabilities see note group lessor treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms impact covid pandemic group assessed certain accounting matters generally require consideration forecast financial information taking account potential future impacts covid pandemic accounting matters assessed included limited groups provisions product returns allowances doubtful accounts trade lease receivables inventory allowances carrying value goodwill intangible assets property plant equipment defined benefit pension plan assets liabilities continued negative impacts pandemic may impact matters bad debt expenses overdue receivables remained relatively low levels significant costs idle manufacturing capacity inventory writeoffs could directly attributed covid factors minor additional covidrelated costs incurred construction projects intangible asset impairment charges chf million incurred result delay clinical trials partly caused covid spark therapeutics haemophilia programme see note impairment issues noted goodwill intangible assets directly attributed pandemic impairment issues directly attributed pandemic noted financial assets although volatility global markets corresponding impact carrying value equity investments held fair value similarly certain volatility fair value pension assets discount rates first half situation largely stabilised end year exceptional funding payments groups pension plans currently foreseen significant impact areas assessed groups annual financial statements group continue monitor areas increased judgements risk material changesfinance report notes roche group consolidated financial statements roche group operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes legal safety environmental services subdivisional information also presented roche pharmaceuticals chugai operating segments within pharmaceuticals division divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets equity compensation plan expenses roche group notes roche group consolidated financial statements finance report pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination results within division operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets equity compensation plan expenses finance report notes roche group consolidated financial statements roche group net assets millions chf assets liabilities net assets december net operating assets pharmaceuticals diagnostics corporate total current income tax net assets liabilities deferred tax net assets liabilities defined benefit plan net assets liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities total net assets disclosed note net operating assets pharmaceuticals division deferred tax net assets liabilities group december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published balance sheet provided note net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets december roche pharmaceuticals chugai elimination within division pharmaceuticals division disclosed note net operating assets roche pharmaceuticals december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published balance sheet provided note roche group notes roche group consolidated financial statements finance report information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment rightofuse assets ntangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenuefinance report notes roche group consolidated financial statements roche group disclosed note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative balance sheet december restated details additional segment net operating assets reported total chf million given transition impact ifrs segment net operating assets millions chf january assets liabilities net assets roche pharmaceuticals chugai pharmaceuticals division diagnostics division corporate total operating lease liabilities group major customers total three us national wholesale distributors represent approximately third groups revenues three us national wholesale distributors mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues roche pharmaceuticals operating segment residual diagnostics operating segment roche group notes roche group consolidated financial statements finance report revenue disaggregated revenue information disaggregation revenue millions chf revenue revenue contracts revenue contracts revenue customers sources total customers sources total pharmaceuticals division sales therapeutic area oncology immunology neuroscience haemophilia ophthalmology infectious diseases therapeutic areas sales royalty income income outlicensing agreements income disposal products royalties operating income diagnostics division sales business area centralised point care solutions molecular diagnostics diabetes care tissue diagnostics sales royalty income income outlicensing agreements income disposal products royalties operating income total revenue sources primarily relates lease revenue collaboration income counterparty considered customer income profitsharing arrangementsfinance report notes roche group consolidated financial statements roche group grosstonet sales reconciliation pharmaceuticals division grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics division similar reconciling items much lower amounts pharmaceuticals division sales grosstonet reconciliation millions chf gross sales government regulatory mandatory price reductions contractual price reductions cash discounts customer returns reserves others net sales government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities see note provisions sales returns recorded balance sheet provisions see note contract balances receivables millions chf accounts receivable current receivables contracts customers noncurrent receivables contracts customers total receivables current receivables mainly include royalty licensing receivables december total receivables include lease receivables considered receivables contracts customers contract assets millions chf accrued income total contract assets roche group notes roche group consolidated financial statements finance report contract liabilities millions chf deferred income noncurrent deferred income current total contract liabilities movement contract liabilities millions chf january business combinations revenue recognised included contract liability balance beginning year increases due cash received receivable excluding amounts recognised revenue year currency translation effects december revenue recognised relation performance obligations satisfied previous years increase revenue recognised chf million increase chf million relating performance obligations satisfied previous periods mainly due adjustments sales deduction provisions accruals expected sales returns chargebacks allowances respect previous years remaining performance obligations partially unsatisfied longterm contracts remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts diagnostics division minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales transaction price allocated contracts partially unsatisfied performance obligations millions chf contract liability held contract liability held total thereof expected recognised revenue within one year one five years five years total finance report notes roche group consolidated financial statements roche group net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans interest expense lease liabilities total financing costs financial income expense millions chf net gains losses equity investments securities fair value profit loss dividend income equity investments securities fair value profit loss dividend income equity investments securities fair value oci net income equity investments securities interest income debt securities fair value oci amortised cost net gains losses sale debt securities fair value oci net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses gains losses net monetary position hyperinflationary economies net financial income expense associates total financial income expense net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense roche group notes roche group consolidated financial statements finance report hyperinflationary economies since july group considered argentina hyperinflationary economy context ias financial reporting hyperinflationary economies cumulative inflation index last three years exceeds measured national wholesaler price index sistema de ndices de precios mayoristas accordingly group reviewed reporting affiliates argentina necessary restated line ias potential adjustments resulting application ias significant impact groups operating results balance sheet adjustment recorded gains losses net monetary position loss chf million resulting loss purchasing power positive net monetary position groups argentinian affiliates loss chf million income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate stable significant changes local tax rates tax jurisdictions group operates groups effective tax rate increased mainly due lower effect resolution several tax disputes compared transitional effect swiss tax reform impairments goodwill tax deductible also impacted effective tax rate groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits deductions us state tax impacts tax unremitted earnings transitional effect swiss tax reform resolution several tax disputes prior year differences groups effective tax rate finance report notes roche group consolidated financial statements roche group income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities disclosed note deferred tax assets december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published deferred tax assets provided note current income tax liabilities include accruals uncertain tax positions current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december roche group notes roche group consolidated financial statements finance report deferred taxes movements recognised net assets liabilities millions chf property plant equipment rightofuse intangible defined temporary assets assets benefit plans ifferences total year ended december january business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december disclosed note net deferred tax assets liabilities december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published net deferred tax assets liabilities provided note deferred tax net assets temporary differences mainly relate accrued liabilities including lease liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested purpose financial statements total unremitted earnings group regarded permanently reinvested purpose financial statements chf billion december chf billionfinance report notes roche group consolidated financial statements roche group mergers acquisitions note includes transactions accounted business combinations asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations ifrs include acquisitions value acquired companies largely consists rights single product technology cash consideration paid asset acquisitions transaction date subsequent additional contingent payments made upon achievement performancerelated development milestones presented line asset acquisitions disclosed separately subsequent consideration performancerelated development milestones transactions treated asset acquisitions recognised intangible assets specific milestones achieved business combinations group complete business combinations business combinations spark therapeutics inc december group acquired controlling interest spark therapeutics inc spark therapeutics publicly owned us company based philadelphia pennsylvania listed nasdaq spark therapeutics fully integrated commercial company committed discovering developing delivering gene therapies spark therapeutics reported pharmaceuticals division part roche pharmaceuticals operating segment total consideration usd million paid cash annual financial statements accounting spark therapeutics acquisition provisional based preliminary information transaction closed shortly december identification valuation intangible assets assets liabilities finalised identifiable assets acquired liabilities assumed set table business combinations net assets acquired millions chf spark therapeutics property plant equipment rightofuse assets intangible assets product intangibles use product intangibles available use deferred tax assets cash cash equivalents marketable securities deferred tax liabilities noncurrent liabilities deferred income lease liabilities longterm liabilities net assets liabilities net identifiable assets goodwill total consideration cash total consideration roche group notes roche group consolidated financial statements finance report intangible assets include spark therapeutics lead clinical asset spk novel gene therapy treatment haemophilia luxturna spark therapeutics marketed gene therapy treatment patients confirmed biallelic rpe mutationassociated retinal dystrophy inherited retinal disease luxturna first gene therapy receive fda approval european commission granted marketing authorisation luxturna intangible assets also include spark therapeutics clinical preclinical assets fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate valuation performed independent valuer goodwill represents spark therapeutics technological capabilities gene therapy gene therapy manufacturing adenoassociated viral vector engineering immunology furthermore goodwill represents control premium acquired work force expected synergies notably areas research development well commercialisation gene therapies none goodwill expected deductible income tax purposes spark therapeutics accounts receivable comprised gross contractual amounts due chf million expected collectable date acquisition directly attributable transaction costs chf million reported roche pharmaceuticals operating segment within general administration expenses impact acquisition results pharmaceuticals division group material acquisition occurred january management estimates spark therapeutics would contributed revenue approximately chf million net loss tax approximately chf million information provided illustrative purposes necessarily indicative results combined group would occurred spark therapeutics actually acquired beginning year indicative future results combined group cash flows business combinations business combinations net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company total net cash outflow asset acquisitions promedior inc february group acquired controlling interest promedior inc promedior privately owned us company based lexington massachusetts acquisition group obtained rights promediors entire portfolio including phase iiiready asset prm recombinant human pentraxin molecule treatment idiopathic pulmonary fibrosis promedior reported pharmaceuticals division cash consideration paid acquisition date usd million additional contingent payments may made based upon achievement performancerelated milestones stratos genomics inc may group acquired controlling interest stratos genomics inc stratos genomics privately owned us company based seattle washington stratos genomics earlystage sequencing technology company group acquired advance development groups nanopore sequencer acquisition provides group access stratos genomics unique chemistry sequencing expansion stratos genomics reported diagnostics division cash consideration paid acquisition date usd million additional contingent payments may made based upon achievement performancerelated milestonesfinance report notes roche group consolidated financial statements roche group lexent bio inc june group acquired controlling interest lexent bio inc lexent bio privately owned us company based san francisco san diego california acquisition provides group access lexent bios novel multiomics liquid biopsy platforms lexent bio reported pharmaceuticals division cash consideration paid acquisition date usd million additional contingent payment may made based upon achievement performancerelated milestone inflazome ltd september group acquired controlling interest inflazome ltd inflazome privately owned company based dublin ireland acquisition group obtained rights inflazomes portfolio clinical preclinical orally available small molecule nlrp inhibitors inflazome reported pharmaceuticals division cash consideration paid acquisition date eur million additional contingent payments may made based upon achievement performancerelated milestones tmema ltd october group acquired controlling interest tmema ltd tmema privately owned company based brighton united kingdom tmema spun enterprise therapeutics ltd immediately transaction acquisition group gained access portfolio tmema potentiators including lead compound phase clinical trials tmema reported pharmaceuticals division cash consideration paid acquisition date gbp million additional contingent payments may made based upon achievement performancerelated milestones asset acquisitions previously closed group recorded additions product intangible assets related achievement performancerelated milestones chf million nil chf million paid nil asset acquisitions net assets acquired millions chf stratos promedior g enomics lexent bio inflazome tmema total intangible assets product intangibles available use deferred tax assets cash cash equivalents net assets liabilities net identifiable assets fair value previously held equity interest total consideration cash deferred consideration total cash consideration asset acquisitions group complete asset acquisitions cash flows asset acquisitions asset acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid cash acquired company contingent payments related previous acquisitions total net cash outflow roche group notes roche group consolidated financial statements finance report restated balance sheet december annual financial statements accounting spark therapeutics acquisition provisional based preliminary information transaction closed shortly december identification valuation intangible assets assets liabilities finalised result comparative balance sheet information december restated reconciliation balance sheet net assets acquired published previously using provisional acquisition accounting restated amounts reported comparatives using final acquisition accounting required ifrs business combinations presented restated roche group consolidated balance sheet selected items millions chf december originally measurement published adjustment restated goodwill intangible assets deferred tax assets net assets net assets measurement adjustments table closing exchange rate december restated spark therapeutics acquisition net assets acquired selected items millions chf spark therapeutics originally measurement published djustment restated intangible assets product intangibles use product intangibles available use deferred tax assets deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration measurement adjustments table exchange rate date control spark therapeutics acquisition december finance report notes roche group consolidated financial statements roche group global restructuring plans group continued implementation various global restructuring plans initiated prior years global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated costs site consolidation employeerelated costs mainly optimisation enabling functions within drug product network site closure costs included impairment reversal chf million roche group notes roche group consolidated financial statements finance report global restructuring plans major items included employeerelated costs chf million mainly outsourcing operational activities global shared service centres external providers well driving business transformation efficiency gains global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment reversal property plant equipment rightofuse assets accelerated depreciation property plant equipment rightofuse assets gains losses disposal property plant equipment rightofuse assets site closure costs total site closure costs divestment products businesses gains losses divestment subsidiaries gains losses divestment products businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs finance report notes roche group consolidated financial statements roche group global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche group notes roche group consolidated financial statements finance report property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january reclassification rightofuse assets previously reported finance leases implementation ifrs leases january revised business combinations additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january asset acquisitions additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value finance report notes roche group consolidated financial statements roche group classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment reversal charge impairment reversals property plant equipment mainly related global restructuring plans see note impairments property plant equipment recorded mainly idle plant reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties see note capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion roche group notes roche group consolidated financial statements finance report goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge recorded within general administration currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals roche pharmaceuticals product transactions chugai total pharmaceuticals division diagnostics customer areas diabetes care customer area divisional goodwill total diagnostics division disclosed note goodwill december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published goodwill provided note cashgenerating units used allocating goodwill pharmaceuticals division basis use cashgenerating units allocating goodwill pharmaceuticals division follows within roche pharmaceuticals operating segment goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products typically limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions roche pharmaceuticals operating segment cashgenerating unit goodwill arising technology transactions also roche pharmaceuticals operating segment however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products therapeutic area revenues costs corresponding assets products also taken account acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired chugai separate operating segment groups financial reporting separate cashgenerating unit goodwill allocatedfinance report notes roche group consolidated financial statements roche group group allocated goodwill roche pharmaceuticals operating segment listed strategic transactions consist genentech foundation medicine flatiron health spark therapeutics technology transactions consist therapeutic human polyclonals dutalys santaris product transactions consist glycart tanox diagnostics division group made comprehensive reassessment cashgenerating units used allocating goodwill diagnostics division reassessment made light following factors business transformations within diagnostics division notably organisation changes announced second half business development activities diagnostics information solutions area ongoing reprioritisation business activities light covid pandemic developments wider diagnostics business conclusions reassessment follows within diagnostics division goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products either synergistic benefits across wider business limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions diagnostics division cashgenerating unit goodwill arising technology transactions either diagnostics customer areas diabetes care customer area however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products business revenues costs corresponding assets products also taken account cashgenerating unit either diagnostics customer areas diabetes care customer area acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired based reassessment group allocated remaining goodwill roche diagnostics operating segment listed basis reallocation historical amounts goodwill arose individual transactions strategic transactions consist corangeboehringer mannheim technology transactions consist viewics diagnostics customer areas mysugr diabetes care customer area product transactions diagnostics customer areas consist avl medical instruments igen bioveris ventana pvt iquum geneweave biosciences product transactions diabetes care customer area consist disetronic medingo impairment charge diagnostics division assessment potential impairment goodwill diagnostics division carried using cash generating units set impairment charges totalling chf million recorded diagnostics division avl medical instruments acquisition charge chf million recorded full writeoff goodwill avl medical instruments acquisition made acquired avl medical instruments leading supplier blood gas electrolyte analysers pointofcare testing blood gas currently lossmaking expected continue lossmaking according latest business plans diagnostics customer areas business developing replacement product planning substantial research development investments area knowledge around bloodgas business synergies gained avl medical instruments acquisition reflected current goodwill amount play minor incidental role future diagnostics customer areas strategy development nextgeneration product accordingly goodwill deemed disposed fully impaired intangible assets relating acquisition fully amortised previous years roche group notes roche group consolidated financial statements finance report geneweave biosciences acquisition charge chf million recorded full writeoff goodwill geneweave biosciences acquisition made acquired geneweave biosciences focused advancing clinical microbiology diagnostic solutions supporting healthcare providers fight drugresistant bacteria acquisition date product intangible assets available use totalling chf million recorded impairment charges recorded fully write intangible assets factors leading impairments decrease forecasted cash flows following change timelines future product development pricing penetration rate due updated market size assumptions updated assumptions timelines research development expenses production costs timelines delayed part due reprioritisation resources covidrelated projects currently unclear whether future revenues support carrying value goodwill synergistic benefits products business would incidental accordingly goodwill deemed disposed fully impaired impairment charge charge chf million recorded diagnostics division partial writeoff goodwill related diabetes care business impairment result revised market assumptions related blood glucose monitoring area slower expected growth parts business value use value use calculated using discounted expected cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate groups weighted average cost capital cashgenerating units integrated operations across large parts group derived capital asset pricing model using data capital markets including government twentyyear bonds assessing value use cash flow projections based recent longterm forecasts approved management longterm forecasts include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation key assumptions used calculations period cash flow projections included longterm forecasts terminal value growth rate discount rate key assumptions used valueinuse calculations period terminal period terminal cash flow value discount rate cash flow value discount rate p rojections growth rate tax p rojections growth rate tax pharmaceuticals division years na years na diagnostics division years years cashgenerating units terminal value growth respective rate exceed longterm projected growth rate relevant market fair value less costs disposal goodwill arising chugai acquisition fair value less costs disposal determined reference publicly quoted price chugai shares sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions would cause carrying values goodwill exceed recoverable amounts december finance report notes roche group consolidated financial statements roche group intangible assets intangible assets movements carrying value assets millions chf product product intangibles intangibles use available use intangibles total january cost accumulated amortisation impairment net book value year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group disclosed note intangible assets december restated following finalisation valuation net assets acquired related spark therapeutics acquisition reconciliation previously published intangible assets provided note marketing intangibles technology intangibles previously presented separately aggregated intangibles comparative information adjusted roche group notes roche group consolidated financial statements finance report significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use rozlytrek ignyta acquisition roche pharmaceuticals years esbriet intermune acquisition roche pharmaceuticals year xofluza shionogi licence transaction roche pharmaceuticals years flatiron health acquisition roche pharmaceuticals years gavreto blueprint medicines licence transaction roche pharmaceuticals years luxturna spark therapeutics acquisition roche pharmaceuticals years foundation medicine acquisition roche pharmaceuticals years brahms licence transaction diagnostics years kapa acquisition diagnostics years product intangibles available use spk haemophilia gene therapy spark therapeutics acquisition roche pharmaceuticals na sarepta licence transaction roche pharmaceuticals na inflazome acquisition roche pharmaceuticals na promedior acquisition roche pharmaceuticals na atea licence transaction roche pharmaceuticals na spk haemophilia b gene therapy spark therapeutics acquisition roche pharmaceuticals na stratos genomics acquisition diagnostics na gavreto blueprint medicines licence transaction roche pharmaceuticals na biontech licence transaction roche pharmaceuticals na dicerna licence transaction roche pharmaceuticals na intangibles technology intangibles use adaptive licence transaction roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total finance report notes roche group consolidated financial statements roche group internally generated intangible assets december commercial software intangible assets amounted chf million nil included intangibles group internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations asset acquisitions separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lowerthananticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million recorded major items related charge chf million partial impairment intangible asset spk novel gene therapy treatment haemophilia acquired part spark therapeutics acquisition impairment result delay clinical trials partly impacted covid pandemic leading reduced sales expectations asset concerned yet amortised written estimated recoverable amount chf million charge chf million partial impairment intangible asset luxturna marketed gene therapy treatment patients inherited retinal disease due mutations copies rpe gene acquired part spark therapeutics acquisition impairment result reduced sales expectations asset concerned written estimated recoverable amount chf million intangible asset continues amortised remaining estimated useful life years impairment charges pharmaceuticals division impairment charges totalling chf million recorded major items related charge chf million full impairment compound purchased separately driven change development plan asset concerned yet amortised fully written charge chf million following clinical data assessment two compounds assets concerned yet amortised fully written charge chf million due decision stop development compound alliance partner asset concerned yet amortised fully written charge chf million partial impairment compound developed together alliance partner mainly driven reduced revenue forecasts asset concerned yet amortised partially written charge chf million due decision stop development compound related collaboration activities alliance partner asset concerned yet amortised fully written charge chf million due decision stop development compound purchased separately asset concerned yet amortised fully written roche group notes roche group consolidated financial statements finance report diagnostics division impairment charges totalling chf million recorded related charge chf million impairment molecular diagnostics product intangibles use acquired part geneweave acquisition main factors leading updated assumptions timelines research development expenses production costs asset concerned amortised fully written charge chf million impairment sequencing business product intangibles use acquired part ariosa acquisition mainly due change timelines launch related sequencing products asset concerned amortised fully written potential commitments alliance collaborations purchase agreements within next three years group party inlicensing similar arrangements alliance partners intangible asset purchase agreements third parties including asset acquisitions arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments within next three years set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf millionfinance report notes roche group consolidated financial statements roche group accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable allowances doubtful accounts movements recognised allowance millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expenses recorded marketing distribution costs totalled chf million expense chf million marketable securities marketable securities millions chf equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci time accounts three months amortised costs total marketable securities marketable securities held fund management purposes primarily denominated us dollars euros swiss francs money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities roche group notes roche group consolidated financial statements finance report cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents noncurrent assets noncurrent assets millions chf equity investments fair value oci equity investments fair value profit loss loans receivable restricted cash receivables contracts customers receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets equity investments designated fair value oci mainly investments private companies pharmaceutical sector held part groups strategic alliance effortsfinance report notes roche group consolidated financial statements roche group current assets current assets millions chf accrued interest income derivative financial instruments restricted cash cash collateral receivables receivables contracts customers receivables total financial current assets prepaid expenses accrued income taxes recoverable assets total nonfinancial current assets total current assets accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income lease liabilities longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits following implementation ifrs leases see note noncurrent lease liabilities chf million recorded mainly leases formerly classified operating leases group lessee effective january roche group notes roche group consolidated financial statements finance report current liabilities current liabilities millions chf deferred income lease liabilities accrued payroll related items interest payable derivative financial instruments cash collateral payables accrued chargebacks allowances separately payable accrued royalties commissions accrued liabilities total current liabilities following implementation ifrs leases see note current lease liabilities chf million recorded mainly leases formerly classified operating leases group lessee effective january finance report notes roche group consolidated financial statements roche group provisions contingent liabilities provisions movements recognised liabilities millions chf contingent legal environmental restructuring consideration p rovisions provisions provisions provisions p rovisions total year ended december january reclassification lease liabilities implementation ifrs leases january revised additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december chf million provisions utilised chf million chf million chf million included cash flows operating activities chf million chf million included cash flows business combinations payments made deferred contingent consideration arrangements see note roche group notes roche group consolidated financial statements finance report legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict part regular review litigation matters management reassessed provisions recorded certain litigation matters based development various litigations notably accutane case us provisions previously held released resulted income chf million major element expenses legal cases show net income chf million included general administration net expenses chf million details major legal cases outstanding disclosed environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland net environmental expenses nil net expense chf million groups procedures environmental protection included annual report pages include actions taken group regard climate change notably groups commitment reduce greenhouse gas emissions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate resourcing flexibility plans well redesign strategic realignment manufacturing network diagnostics division significant provisions associated programmes address longterm strategy corporate relate initiatives outsourcing operational activities global shared service centres external providers details given note contingent consideration provisions group party certain contingent consideration arrangements arising business combinations significant provisions discounted using average discount rate time value money material additional details measurement total potential payments arrangements provided note provisions provisions relate items shown table exception employee provisions timing cash outflows nature uncertain provisions millions chf sales returns employee provisions items total provisions december items included provisions previously recorded estimated amount potential obligation past royalties relating pdl inhibitor litigation described november settlement agreement reached dispute agreed cash settlement recorded provisionsfinance report notes roche group consolidated financial statements roche group contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note legal cases december provisions legal cases chf million chf million mainly related legal cases pharmaceuticals division chf million chf million diagnostics division chf million chf million provisions recorded cases settled mainly relating meso diagnostics legal case pharmaceuticals legal matters listed accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl us district court middle district florida tampa division august mdl closed pendency mdl district court granted summary judgment favour hlr federal ibd cases proceeded affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county february superior court new jersey law division atlantic county held eightday evidentiary hearing whether plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february order july new jersey appellate division reversed order excluding plaintiffs experts testifying accutane causes crohns disease reinstated dismissed cases finding trial court wrongfully barred plaintiffs expert witnesses hlr filed petition review new jersey supreme court granted december august supreme court issued decision whether plaintiffs experts testify accutane causes crohns disease supreme court reversed judgment new jersey appellate division concluded trial court properly excluded experts thereby dismissing cases alleging accutane caused plaintiffs crohns disease plaintiffs appeal crohns disease cases permanently dismissed may superior court entered order granting summary judgment dismissing cases filed new jersey residents basis drug label adequate matter law since july superior court granted hlrs motion summary judgment adequacy label post ingestion cases jurisdictions superior court applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would resulted cases dismissed july new jersey appellate division affirmed dismissal cases reinstated judgments cases based strength hlrs warnings hlr dismissed plaintiffs filed petitions review new jersey supreme court granted december october supreme court issued decision cases reversed judgment new jersey appellate division reinstated cases basis drug label adequate matter law since plaintiffs appeal cases permanently dismissed roche group notes roche group consolidated financial statements finance report january october superior court entered orders granting summary judgment dismissing cases failure prove accutane proximately caused ulcerative colitis plaintiffs appealed decisions february march superior court held evidentiary hearing whether plaintiffs experts testify accutane causes ulcerative colitis april superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing ulcerative colitis cases subject superior courts april order plaintiffs appealed decisions december hlr defending pending actions approximately cases appeal hearing january january new jersey appellate division issued decision whether plaintiffs experts testify accutane causes ulcerative colitis affirmed trial courts ruling concluded trial court properly excluded experts thereby dismissing cases alleging accutane caused plaintiffs ulcerative colitis plaintiffs filed petition appeal new jersey supreme court may supreme court entered order denying petition plaintiffs appeal remaining cases permanently dismissed supreme court dismissed previously cases matter us concluded avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche appealed verdict tar consiglio di stato july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration january european court justice rendered decision five questions referred european court justice consiglio di stato july consiglio di stato issued final verdict case upheld verdicts agcm tar respect fine agcm matter concluded italian ministry health italian regions notified group intention seek damages related matter january french competition authority fca issued statement objections roche genentech novartis regarding anticompetitive practices concerning commercialisation avastin lucentis france fca alleges roche genentech novartis abused collective dominant position french market treatment wet agerelated macular degeneration september fca issued decision finding roche genentech novartis infringed competition law imposed fine eur million roche genentech roche genentech appealed decision december liability held amount fine included accounts payable within line item payables see note fine paid protest avoid additional penalty fees due later february addition group challenging policies regulations allowing offlabelunlicensed use reimbursement economic reasons various countries group vigorously defending matters outcome matters determined timefinance report notes roche group consolidated financial statements roche group pdl inhibitor litigation july bristolmyers squibb co bms filed lawsuit genentech inc genentech delaware us bms alleges genentechs sale tecentriq infringes us patent bms seeking judgment favour finding wilfulness monetary damages october genentech filed answer counterclaims seeking declaratory judgment invalidity patent may bms genentech agreed drop lawsuit without prejudice case refiled later date november bms genentech reached settlement agreement dispute terms agreement two parties concluded royalty agreement future worldwide sales tecentriq genentech made cash settlement past royalties provisions previously recorded estimated amount potential obligation past royalties agreed cash settlement recorded provisions matter concluded average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us one dismissed case canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time meso litigation february roche diagnostics corporation roche filed lawsuit us district court district delaware meso scale diagnostics llc meso patent infringement case involving certain us patents owned bioveris corporation bioveris company acquired group meso holds limited exclusive licence use certain aspects electrochemiluminescence ecl detection technology roche meso disagree scope licence lawsuit seeking declaratory judgment get judicial clarification roche infringing mesos licence november jury found roches use patents infringed scope mesos licence injunction granted jury awarded meso usd million damages posttrial motions filed parties meso moved enhancement prejudgment interest postjudgment royalties court hearing took place may december us district court issued final order judgment jury award confirmed mesos request enhanced damages denied group appeal decision addition pharmaceuticals legal cases listed currently provisions recorded potential future obligations confirmed occurrence nonoccurrence uncertain future events obligation measured sufficient reliability roche group notes roche group consolidated financial statements finance report hemlibra litigation may baxalta inc baxalta gmbh together baxalta subsidiaries takeda pharmaceutical company limited filed patent infringement declaratory judgment patent infringement suit us district court district delaware alleging genentech chugai pharmaceutical co ltd chugai currently imminently would manufacture use sell offer sale import us hemlibra would infringe baxaltas us patent baxalta seeking judgment infringement injunctive monetary relief attorneys fees costs expenses may genentech served complaint genentechs response counterclaims complaint filed june june chugai waived service september chugai filed motion dismiss complaint lack personal jurisdiction december baxalta filed request preliminary injunction genentech inhibitor patients would subject injunction hearing held us district court district delaware june hearing baxalta withdrew request preliminary injunction inhibitor patients june baxalta submitted new proposed preliminary injunction order genentech would permitted sell hemlibra inhibitor patients noninhibitor patients currently hemlibra whether clinical trials selected noninhibitor patients additional medically diagnosed condition rendered factor viii therapies impracticable august us district court ruled baxalta denying request injunction september chugai dismissed case february us district court issued final judgment favour genentech stating hemlibra infringe baxaltas patent based courts definition key terms related patent february baxalta appealed decision august appeals court reversed claim construction ruling us district court favour genentech remanded case back us district court group vigorously defending matter outcome matter determined time march case brought baxalta chugai japan tokyo district court ruled favour chugai notably hemlibra infringe baxaltas patent may baxalta appealed decision october japanese intellectual property high court issued ruling upholding tokyo district courts decision baxalta filed appeal japanese supreme court august japanese supreme court decided accept baxaltas final appeal therefore decision japanese intellectual property high court final baxaltas patent japan valid infringed hemlibra pending legal actions japan terminated matter japan concluded iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device companies named defendants complaint filed federal district court district columbia us behalf us servicemembers relatives allege killed injured iraq iraq lawsuit complaint alleges defendants violated us antiterrorism act various state laws providing funding terrorist organisations sales practices pursuant pharmaceutical andor medical device contracts iraqi ministry health addition fhlr received inquiry july us department justice connection anticorruption investigation relating activities iraq including interactions iraqi government certain matters alleged iraq lawsuit october us department justice closed inquiry fhlr july federal district court granted defendants motions dismiss plaintiffs appealed decision group vigorously defending matter outcome matter determined time tamiflu qui tam litigation roche holding ltd roche holding hoffmannla roche inc hlr genentech inc genentech served lawsuit filed relator us district court district maryland qui tam whistleblower provisions false claims act lawsuit originally filed seal years earlier behalf us government various us state governments lawsuit alleges certain improper conduct group respect sales tamiflu us government various us state governments us department justice declined intervene lawsuit january group filed motion dismiss september plaintiff dismissed complaint roche holding genentech district court denied hlrs motion summary judgment group vigorously defending matter outcome matter determined timefinance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january reclassification lease liabilities implementation ifrs leases na january revised proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt changes financing cash flows net gains losses redemption repurchase bonds notes amortisation debt discount financing costs business combinations asset acquisitions net foreign currency transaction gains losses currency translation effects changes foreign exchange rates changes fair values hedging instruments changes december bonds notes commercial paper amounts due banks financial institutions borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche group notes roche group consolidated financial statements finance report bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usba notes due september principal usd billion outstanding usd billion isin usbb notes due january principal usd billion isin usbm notes due september principal usd billion outstanding usd billion isin usbn na notes due september principal usd billion outstanding usd billion isin usbe na notes due november principal usd billion outstanding usd billion isin usbj na notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na notes due september principal usd billion isin usbp na notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na us dollar notes floating rate notes due september principal usd billion isin usaz na euro medium term note programme fixed rate notes due march principal usd billion isin xs notes due march principal eur billion outstanding eur billion isin xs notes due february principal eur billion isin xs na notes due august principal gbp billion outstanding gbp billion isin xs na notes due february principal eur billion isin xs swiss franc bonds fixed rate bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch na genentech senior notes senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes group issue bonds notes issuance bonds notes group issue bonds notes redemption repurchase bonds notes group repay bonds notes redemption repurchase bonds notes redemption us dollar notes due date september group repaid fixed rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes due date september group repaid floating rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes december group resolved exercise option call early redemption fixed rate notes principal amount usd billion par three months scheduled due date march cash outflow chf million plus accrued interest effective interest rate notes december group completed tender offer redeem following instruments usd million fixed rate notes due september effective interest rate usd million fixed rate notes due september effective interest rate usd million fixed rate notes due september effective interest rate usd million fixed rate notes due november effective interest rate usd million fixed rate notes due july effective interest rate usd million fixed rate notes due march effective interest rate cash outflow chf million plus accrued interest loss redemption chf million included chf million paid bank fees roche group notes roche group consolidated financial statements finance report cash flows redemption repurchase bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme us dollar notes us dollar notes total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd committed credit line available backstop supporting commercial paper program usd billion december july previously existing committed credit lines refinanced one new committed credit line initial maturity five years maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies average interest rate december amounts outstanding chf million chf million due within one yearfinance report notes roche group consolidated financial statements roche group equity attributable roche shareholders changes equity attributable roche shareholders millions chf share retained fair value hedging translation c apital earnings reserves reserves reserves total year ended december january net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax roche group notes roche group consolidated financial statements finance report changes equity attributable roche shareholders millions chf share retained fair value hedging translation c apital earnings reserves reserves reserves total year ended december january net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced chf billion chf billion allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policyfinance report notes roche group consolidated financial statements roche group share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares december shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition duration pool extended indefinite period shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis holding ag basel owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result total distribution shareholders chf million subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf million fair value nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note reserves fair value reserve december fair value reserve represents cumulative net change fair value financial assets fair value oci asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs roche group notes roche group consolidated financial statements finance report subsidiaries chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse january chugai announced split common stock effective july number issued shares increased threeforone split chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany itemsfinance report notes roche group consolidated financial statements roche group roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement chugai shall offer roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery roche group notes roche group consolidated financial statements finance report noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests finance report notes roche group consolidated financial statements roche group employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plan us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation roche group notes roche group consolidated financial statements finance report pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contribution based certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans underfunding would normally remedied additional company contributions payments made group pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contribution based minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai made additional voluntary contributions jpy billion pension plans jpy billion chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan postemployment benefit opeb plans represent approximately groups defined benefit obligation consist postemployment healthcare life insurance schemes mainly us plans mainly unfunded andor contributory employees group reimbursing retired employees directly financial resources groups major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement finance report notes roche group consolidated financial statements roche group funding status funding groups various defined benefit plans responsibility respective senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations ifrs funding status funded defined benefit plans increased reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans respective senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations postemployment benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain chf million gain chf million excludes actual return reimbursement rights recognition plan assets limited present value economic benefits available refunds plans reductions future contributions plans roche group notes roche group consolidated financial statements finance report defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets reimbursement rights remeasurements plan assets reimbursement rights currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property primarily private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf millionfinance report notes roche group consolidated financial statements roche group defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee result proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contribution based minimum guarantee remain open new employees defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years roche group notes roche group consolidated financial statements finance report actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour average life expectancy assumed individual age follows defined benefit plans average life expectancy age major schemes years male female country mortality table switzerland bvg projected cmi model united states pri projected mp germany heubeck tables g projected cmi model mortality assumptions used pension plans switzerland based bvg applying continuous mortality investigation cmi model longterm rate used longevity improvements group used mortality assumptions pension plans germany heubeck tables g applying cmi model longterm rate longevity improvements financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases taking account expected inflation rates amongst factors expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments usfinance report notes roche group consolidated financial statements roche group sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf increase decrease defined benefit obligation life expectancy year increase discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional voluntary contributions related chugai benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plans roche group notes roche group consolidated financial statements finance report equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai plans total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai plans exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period starting rights nontradable equitysettled awards tenyear duration vest phased basis four years rights granted sevenyear duration vest phased basis three yearsfinance report notes roche group consolidated financial statements roche group roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands c ontractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities rsus vest phased basis four years subject performance conditions rsus granted vest threeyear period currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period starting roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche group notes roche group consolidated financial statements finance report roche performance share plan group offered future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme remains one annual threeyear cycle roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number shares nonvoting equity securities individual award granted amount shares nonvoting equity securities allocated depends upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award granted result zero two shares nonvoting equity securities value adjustment depending upon achievement performance targets new psp awards granted roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years allocated recipients feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards tenyear duration vest phased basis four years options granted sevenyear duration vest phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable finance report notes roche group consolidated financial statements roche group roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands c ontractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche roche stocksettled stock restricted stock roche appreciation rights unit plan option plan progressively progressively progressively vesting period years years years contractual life years na years number granted year thousands weighted average fair value chf model used binomial market pricea binomial inputs option pricing model share price grant date chf exercise price chf expected volatility b na expected dividend yield na early exercise factor c na expected exit rate na fair value roche rsus equivalent share price date grant b volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream c early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche group notes roche group consolidated financial statements finance report leases implementation ifrs leases effective january group implemented ifrs leases ifrs replaced existing leases guidance including ias leases sets principles recognition measurement leases main effect group lessee ifrs introduced single onbalance sheet lease accounting model requires lessee recognise assets liabilities leases lease liability reflects present value remaining lease payments rightofuse asset corresponds lease liability adjusted payments made lease commencement date lease incentives items related lease agreement result rightofuse assets totalling chf million lease liabilities totalling chf million recorded balance sheet effective january transition impacts balance sheet shown table transition impact ifrs roche group consolidated balance sheet selected items millions chf originally published application revised december ifrs january property plant equipment rightofuse assets current assets longterm debt noncurrent provisions noncurrent liabilities shortterm debt current provisions current liabilities total net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity weighted average incremental borrowing rate applied lease liabilities recognised transition operating lease commitments finance lease liabilities reported annual financial statements applying previous leasing standard ias reconciled lease liabilities recognised transition ifrs shown table reconciliation lease liabilities recognised transition january millions chf operating lease commitments undiscounted reported december applying ias finance lease liabilities reported december applying ias recognition exemption shortterm leases leases lowvalue assets lease arrangements commencement date december discounting lease liabilities recognised transition january applying ifrs thereof noncurrent liabilities current liabilities total group lessor application new standard material effectsfinance report notes roche group consolidated financial statements roche group transition approach use practical expedients group applied cumulative catchup method transition cumulative effect adopting ifrs recognised adjustment opening balance retained earnings january restatement comparative information rightofuse assets generally measured amount equal lease liability adjusted payments made lease commencement date lease incentives items related lease agreement recognised balance sheet immediately date initial application rightofuse assets measured carrying amount ifrs applied since lease commencement date discounted using groups incremental borrowing rate january practical expedients permitted standard used notably reassess upon transition whether existing contract contains lease definition lease ifrs applied contracts entered changed january recognition exemptions shortterm leases leases lowvalue assets motor vehicles separate nonlease components instead account lease nonlease components single lease component apply ias onerous leases instead performing impairment review group lessee group enters leasing transaction lessee mainly reasons convenience flexibility group good cash generation ability enjoys strong longterm investment grade credit ratings therefore typically enter leasing arrangements financing considerations main areas leases group entered property offices apartments small number leases represent value cars mostly sales representatives office equipment photocopiers similar roche group notes roche group consolidated financial statements finance report rightofuse assets reported groups leases shown table rightofuse assets movements carrying value assets millions chf buildings land improve machinery land ments equipment total year ended december january cumulative catchup previously reported operating leases implementation ifrs reclassification property plant equipment previously reported finance leases implementation ifrs january revised business combinations additions disposals depreciation impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations asset acquisitions additions disposals depreciation impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value classification impairment reversal charge rightofuse assets millions chf cost sales marketing distribution research development general administration total impairment reversal charge impairment charges rightofuse assets mainly related global restructuring plans see note income chf million recognised related impairment reversal rightofuse assets lease arrangement assessed onerous contract finance report notes roche group consolidated financial statements roche group liabilities reported groups leases shown table leases movements carrying value recognised liabilities millions chf january cumulative catchup previously reported operating leases implementation ifrs na reclassification debt previously reported finance lease obligations implementation ifrs na january revised increase new lease arrangements repayment lease liabilities business combinations asset acquisitions disposals interest expense lease liabilities currency translation effects december noncurrent lease liabilities current lease liabilities total lease liabilities maturity analysis lease liabilities given note liquidity risk section shortterm leases leases lowvalue assets accounted using recognition exemption permitted ifrs expenses shortterm leases recognised straightline basis mainly include shortterm property leases employee apartments amount reported chf million chf million expenses leases lowvalue assets recognised straightline basis mainly include certain office equipment amount reported chf million chf million expenses variable lease payments included measurement lease liabilities chf million chf million income subleasing rightofuse assets chf million chf million group enter sale leaseback transactions major cash flows respect leases group lessee shown table leases cash flows millions chf included cash flows operating activities included cash flows financing activities total lease payments cash flows operating activities include cash flows shortterm lease leases lowvalue assets variable lease payments cash flows financing activities include payment interest principal portion lease liabilities well prepayments made lease commencement date leases committed yet commenced july foundation medicine inc fmi entered binding lease agreement third party lease laboratory office space building boston us constructed landlord location currently known boston seaport according agreement fmi committed lease building years commencement date lease currently expected second half initial rightofuse asset lease liability related agreement estimated approximately usd million based current assumptions roche group notes roche group consolidated financial statements finance report group lessor diagnostics division group enters certain contracts include placement diagnostics instruments supply reagents consumables servicing arrangements depending upon term agreement instrument placement may result either finance lease operating lease group performs thorough customer assessment new leasing agreements signed usually group also retains rights terminate modify contracts certain conditions met finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income following amounts recorded income respect finance leases finance leases selected items income millions chf selling profit difference sales cost sales finance income net investment lease currently group income variable lease payments finance leases carrying amount net investment finance leases reported receivables chf million chf million finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one two years two three years three four years four five years five years total unearned finance income na na unguaranteed residual value na na net investment lease operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements income operating leases recognised revenue straightline basis lease term lease revenue entirely based variable lease payments subject subsequent reagent sales performance obligations reagents satisfied lease income chf million chf million included sales chf million chf million relates variable lease payments depending upon index ratefinance report notes roche group consolidated financial statements roche group leased assets reported within property plant equipment shown table machinery equipment subject operating leases movements carrying value assets millions chf leased use total leased use total january cost accumulated depreciation impairment net book value year ended december january reclassification rightofuse assets implementation ifrs leases na na na january revised business combinations asset acquisitions additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value undiscounted amounts expected received noncancellable operating leases shown table operating leases future minimum lease receipts noncancellable leases millions chf within one year one two years two three years three four years four five years five years total minimum receipts roche group notes roche group consolidated financial statements finance report earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf finance report notes roche group consolidated financial statements roche group statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics divisions calculated using indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns net gain loss disposal products adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche group notes roche group consolidated financial statements finance report cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing also included cash flows indicate groups transactions providers equity debt financing cash flows lease payments also included within financing activities cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai noncontrolling interests dividend withholding tax total liabilities arising financing activities movements carrying value recognised assets liabilities millions chf cash principal derivative collateral p ortion financial receivables interest lease nstruments payables debt p ayable l iabilities net net total year ended december january cash flows outflow inflow noncash changes financing costs business combinations fair value foreign exchange rates december year ended december january cash flows outflow inflow noncash changes financing costs business combinations asset acquisitions fair value foreign exchange rates december significant noncash transactions significant noncash transactions none except leasing transactions group lessee see note finance report notes roche group consolidated financial statements roche group risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part longterm forecasting controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits types authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets group considers financial asset default counterparty unlikely pay obligations group full assessing whether counterparty default group considers qualitative quantitative indicators eg overdue status based data developed internally certain financial assets also obtained external sources major part groups receivables past due days relate public customers risk default public customers considered low group reasonable supportable information demonstrate lagging default criterion appropriate particular customer segment accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts group uses allowance matrix estimate allowance doubtful accounts trade receivables expected credit loss ecl rate based groups historical experience groups expectation economic conditions period receivables expected paid roche group notes roche group consolidated financial statements finance report customer credit risk exposure based accounts receivable days overdue millions chf overdue overdue overdue credit total current months months year impaired december gross carrying amount groups expected credit loss rate allowance doubtful accounts december gross carrying amount groups expected credit loss rate allowance doubtful accounts december groups combined trade receivables balance three us national wholesale distributors mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral considered measure expected credit losses trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables chf billion chf billion public private customers countries group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue net allowances doubtful accounts allowances nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total finance report notes roche group consolidated financial statements roche group cash marketable securities excluding equity securities december group cash marketable securities excluding equity securities chf billion chf billion subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly cash cash equivalents held banks financial institutions predominantly rated investment grade based moodys standard poors ratings cash shortterm time deposits subject rules limit groups exposure individual financial institutions impairment cash cash equivalents measured month expected credit losses ecl basis reference external credit ratings counterparties reflect short maturities exposures group considers cash cash equivalents low credit risk based external credit ratings investments marketable securities excluding equity securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity counterparties credit rating least baa moodys bbb standard poors credit risk counterparties external ratings investment grade rating closely monitored reviewed individual basis rating analysis cash marketable securities excluding equity securities market values millions chf fair value fair value oci amortised costs oci amortised costs total month ecl month ecl total month ecl month ecl aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amounts loss allowance loss allowance related fair value oci affect carrying amount marketable securities excluding equity securities booked corresponding oci reserve instead debt securities amortised cost fair value oci investment grade therefore considered low risk thus impairment allowance determined month expected credit losses ecl reference external credit ratings counterparties debt securities group observed significant increase credit risk would require application lifetime expected credit losses impairment model addition material movements loss allowance respectively master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses financial assets excluding equity investmentssecurities impairment losses none roche group notes roche group consolidated financial statements finance report liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit line various financial institutions totalling chf billion chf billion chf billion chf billion serve backstop line commercial paper program july previously existing committed credit lines refinanced one new committed credit line initial maturity five years remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf less carrying value total year years years years december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities derivative financial instruments total financial liabilities december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility mainly pharmaceuticals division future minimum takeorpay commitments within agreements total potential commitment group chf billion december chf billion market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equityfinance report notes roche group consolidated financial statements roche group valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component decreased due reduction underlying interest rates across major currencies foreign exchange component decreased due favourable exposure mix price component increased mainly due higher prices equity investments equity securities foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro groups foreign exchange risk management strategy preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously immunise unfavourable developments foreign exchange rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments shortterm debt groups interest rate risk management strategy optimise net interest result group may use forward contracts options interest rate swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events roche group notes roche group consolidated financial statements finance report capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined chugai management financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost l iabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities finance report notes roche group consolidated financial statements roche group carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost l iabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche group notes roche group consolidated financial statements finance report fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total december marketable securities equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value december marketable securities equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date equity investments fair value oci fair value profit loss based valuation model uses recently published observable market data group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year nonefinance report notes roche group consolidated financial statements roche group level fair values details determination level fair value measurements set contingent consideration arrangements millions chf january arising business combinations utilised settlements total gains losses included income statement unused amounts reversed recorded within general administration additional amount created recorded within general administration discount unwind included financing costs total gains losses included comprehensive income currency translation effects december contingent consideration arrangements group party certain contingent consideration arrangements including business combinations fair values contingent consideration business combinations determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rates higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements arising business combinations could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment dutalys roche pharmaceuticals santaris roche pharmaceuticals genia diagnostics others various diagnostics december roche group notes roche group consolidated financial statements finance report derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements movements cash collateral receivable accrued liability millions chf january net cash delivered group fair value currency translation effects december hedge accounting described groups risk management strategy hedge transaction exposures arising foreign currency flows monetary positions held foreign currencies well generate appropriate mix fixed floating rate exposures level hedging depends market conditions business requirements group group designates specific interest rate risk management objective ensure predetermined level interest rate risk exposure floating rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments reporting date ensure economic relationship exists hedged item hedging instrument group performs qualitative assessment hedge effectiveness using critical terms match method critical terms hedged items hedging instruments match group concludes risks hedged hedged items hedging instruments sufficiently aligned inherent mismatch hedging relationship hedge ratio applies actual quantities hedged hedge accountingfinance report notes roche group consolidated financial statements roche group accounting treatment sources ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential sources ineffectiveness assessment method interest rate foreign exchange rate fluctuations cash flow hedge counterparty credit risk critical terms match foreign exchange rate fluctuations cash flow hedge lower volume hedged items critical terms match counterparty credit risk interest rate fluctuations fair value hedge counterparty credit risk critical terms match ineffective portion hedge accounting recognised income statement included financial income expense measured using hypothetical derivative method cash flow hedges cumulative dollar offset method fair value hedges december december respectively none potential sources ineffectiveness individually collectively resulted material amounts actual ineffectiveness reported hedge accounting relationships table shows fair values nominal amounts derivative financial instruments including range maturity nominal amount hedging instruments designated hedging instruments cash flow hedge fair value hedge december respectively group following cash flow hedges fair value hedges designated qualifying hedge relationship fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total roche group notes roche group consolidated financial statements finance report fair values derivative financial instruments used hedge accounting included current assets see note current liabilities see note groups approach managing market risk including interest rate risk foreign currency risk discussed market risk section note cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro december instruments recorded net fair value liability chf million net fair value liability chf million ineffective portion chugai entered forward exchange contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value assets chf million fair value liabilities chf million fair value assets chf million fair value liabilities chf million ineffective portion none hedging instruments currently held applying hedge accounting affected interbank offered rates ibor reform carrying amount items designated hedged items cash flow hedging relationship millions chf assets liabilities assets liabilities december bonds notes risk hedged crosscurrency swaps interest rate foreign exchange rate fluctuations bonds notes inventories risk hedged forward exchange contracts foreign exchange rate fluctuations inventories hedging reserve continuing hedging relationships millions chf forward cross forward crosscur exchange currency exchange total rency swaps contracts total swaps contracts january gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation effects december entire amount transferred income statement reported financial income expense hedging relationships hedge accounting longer applied none changes hedging reserve within equity shown note finance report notes roche group consolidated financial statements roche group expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow fair value hedges group entered interest rate swaps hedge exposure changes fair value fixedterm debt instruments respect benchmark interest rate december instruments recorded fair value assets chf million fair value assets chf million fair value adjustments chf million recorded interest rate swaps chf million interest rate swaps currently held applying hedge accounting referenced benchmark rate london interbank offered rate libor except hedging instrument hedging portion eur million notes due march fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments groups approach managing market risk including interest rate risk discussed market risk section note carrying amount items designated hedged items fair value hedging relationship millions chf fair value fair value adjustments adjustments liabilities cumulative current year december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes december group resolved exercise option call early redemption fixed rate notes principal amount usd billion par three months scheduled due date march see note resulted termination fair value hedge accounting applied interest rate swaps nominal value usd million fair value less chf million date termination net investment hedges group net investment hedges roche group notes roche group consolidated financial statements finance report related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr jrg duschmal members board directors roche holding ltd dr andreas oeri previously member board directors roche holding ltd stand reelection annual general meeting mr hoffmann received remuneration totalling chf chf dr duschmal received remuneration totalling chf nil dr oeri received remuneration totalling chf chf transactions group individual members shareholder group subsidiaries associates listing group subsidiaries associates included note listing excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associatesfinance report notes roche group consolidated financial statements roche group key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees chairman board directors members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members cec members cec also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring partway year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report disclosed annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report roche group notes roche group consolidated financial statements finance report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan contributions paid members corporate executive committee millions chf roche connect defined benefit plans transactions group various defined benefit plans employees group described note finance report notes roche group consolidated financial statements roche group list subsidiaries associates following listing group subsidiaries associates excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation listed companies share capital equity interest location company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million nonlisted companies share capital equity interest location company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars roche diabetes care argentina sa tigre ars australia roche diabetes care australia pty limited north ryde aud roche diagnostics australia pty limited north ryde aud roche products pty limited sydney aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk usd belgium nv roche sa brussels eur roche diagnostics belgium nv diegem eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp roche group notes roche group consolidated financial statements finance report share capital equity interest location company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai ltd shanghai usd roche diagnostics suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche services americas sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte d'ivoire roche cte d'ivoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark obi aps hadsund dkk roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche diagnostics egypt trading sae giza egp roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp el salvador productos roche el salvador sa de cv antiguo cuscatlan svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur timkl sas montbonnotsaintmartin eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur foundation medicine gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostics automation solutions gmbh ludwigsburg eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche real estate services mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur rox health gmbh berlin eur signature diagnostics gmbh potsdam eur ghana roche products ghana limited accra ghs greece roche hellas sa marousi eur roche diagnostics hellas sa marousi eur guatemala productos roche guatemala sociedad annima guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budaors huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostics india private limited mumbai inr roche products india private limited mumbai inr viewics india private limited pune inr finance report notes roche group consolidated financial statements roche group share capital equity interest location company city millions indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland inflazome limited dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur spark therapeutics ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd hod hasharon ils italy roche diabetes care italy spa monza eur roche diagnostics spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes kuwait roche trading medicines equipment devices medical supplies spc salmiya kwd latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd moka mur mexico productos roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited mount wellington nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn north macedonia roche makedonija dooel skopje eur norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab productos roche interamericana sa prisa panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation rochemoscow jsc moscow rub limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostics rus moscow rub saudi arabia roche diagnostics saudi arabia llc riyadh sar roche products saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur roche group notes roche group consolidated financial statements finance report share capital equity interest location company city millions singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystems pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostics proprietary limited midrand zar roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostics sl sant cugat del valls eur roche farma sa madrid eur sweden roche ab solna sek roche diagnostics scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care switzerland ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd basel chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim irketi istanbul try roche diagnostics turkey anonim irketi istanbul try roche mstahzarlari sanayi anonim irketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diabetes care middle east fzco dubai aed roche diagnostics middle east fzco dubai aed roche pharmaceuticals middle east fzco dubai aed united kingdom flatiron health uk ltd st albans gbp intermune holdings limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics limited burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp spark therapeutics uk ltd london gbp tmema limited welwyn garden city gbp tusk therapeutics limited welwyn garden city gbp finance report notes roche group consolidated financial statements roche group share capital equity interest location company city millions united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc pleasanton usd bioveris corporation indianapolis usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine securities corporation cambridge usd foundation medicine inc cambridge usd genentech usa inc south san francisco usd genentech inc south san francisco usd hoffmannla roche inc little falls usd surviving corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc south san francisco usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc south san francisco usd kapa biosystems inc wilmington usd lexent bio inc south san francisco usd memory pharmaceuticals corp little falls usd promedior inc south san francisco usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche diagnostics seattle inc seattle usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequencing solutions inc pleasanton usd roche tcrc inc little falls usd seragon pharmaceuticals inc south san francisco usd spark therapeutics international holdings inc philadelphia usd spark therapeutics inc philadelphia usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc santa clara usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche pharma vietnam company limited ho chi minh city vnd roche vietnam company limited ho chi minh city usd share capital less local currency units roche group notes roche group consolidated financial statements finance report significant accounting policies consolidation policy subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income revenue sales revenue sale goods supplied product sales services rendered recoded sales sales recognised promise customer contract performance obligation satisfied transferring control promised goods services customer control promised good service refers ability direct use obtain substantially remaining benefits goods services control usually transferred upon shipment delivery upon receipt goods customer services rendered accordance delivery acceptance terms agreed customers goods subject installation instruments sold diagnostics division sales generally recognised upon completion installation customers site customer acceptance amount sales recognised transaction price based consideration group expects receive exchange goods services excluding amounts collected behalf third parties value added taxes taxes directly linked sales contract contains one performance obligation transaction price allocated performance obligation based relative standalone selling pricesfinance report notes roche group consolidated financial statements roche group instruments diagnostics division may sold together goods reagents consumables well services single contract several contracts combined revenue recognition purposes sales recognised upon satisfaction performance obligations contract instruments either sold cash instalment sales transactions otherwise made available customers finance lease operating lease transactions finance leases arrangements group transfers substantially risks rewards ownership customer treated finance lease arrangements income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement interest rates embedded finance lease arrangements approximately market rates income finance leases comparable revenue outright sales finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest rate method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term lease revenue entirely variable subject subsequent reagent sales performance obligation deliver reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise contracts distributors sales recognised goods physically transferred distributor consignment arrangement distributor acts agent cases sales recognised control goods transfers endcustomer distributors commissions presented within marketing distribution commissions similar payments distributors acting principals deducted sales unless payments exchange distinct service consideration received group exchange goods services may fixed variable variable consideration recognised considered highly probable significant revenue reversal occur underlying uncertainty related variable consideration subsequently resolved common elements variable consideration pharmaceuticals division listed government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities provisions sales returns recorded balance sheet provisions group recognises deferred income contract liability consideration received become receivable group transfers promised goods services customer deferred income mainly relates remaining performance obligations goods free charge certain patient access similar programmes reagents consumables services remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales roche group notes roche group consolidated financial statements finance report royalty operating income royalty operating income includes royalty income income outlicensing agreements income disposal products items royalty income earned licence recognised underlying sales recorded licensee income outlicensing agreements typically arises receipt upfront milestone similar payments third parties granting licence product technologyrelated intellectual property ip outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing licences granted usually rights use ip generally unique therefore basis allocating revenue performance obligations makes use residual approach upfront payments licensing fees usually recognised upon granting licence unless income shall deferred performance obligations using residual approach deferred income released recognised revenue performance obligations satisfied milestone payments typically received upon reaching specific scientific milestone development milestone upon achieving certain annual sales milestone commercial milestone development milestone income recognised point time highly probable respective milestone event criteria achieved risk revenue reversal considered remote commercial milestone income accrued recognised revenue highly probable annual sales milestone reached period payments received disposal product similar rights recognised revenue upon transfer control rights extent payments relate performance obligations portion deferred using residual approach recognised revenue activities manufacturing services rendered income profitsharing arrangements collaboration partners recognised underlying sales cost sales recorded collaboration partners also included income services rendered usually part groups primary business activities extent revenue recorded sales recognised control transfers performance obligations satisfied cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition assetfinance report notes roche group consolidated financial statements roche group employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service cost charged appropriate income statement heading within operating results past service cost including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity roche group notes roche group consolidated financial statements finance report property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee policy applicable january inception contract group assesses whether contract contains lease contract contains lease contract conveys right control use identified asset period time exchange consideration group recognises rightofuse asset corresponding lease liability contract contains lease lease commencement date except shortterm leases leases lowvalue assets payments shortterm leases leases lowvalue assets recognised expense straightline basis term respective lease lease liability initially measured present value future lease payments paid lease commencement date lease payments discounted using interest rate implicit lease readily determinable groups incremental borrowing rate respective markets lease payments include fixed payments variable payments depend index rate known lease commencement date payments exercising extension purchase options group reasonably certain exercise lease liability subsequently measured amortised costs using effective interest method remeasured corresponding adjustment related rightofuse asset change future lease payments following contract renegotiation change index rate reassessment options rightofuse asset initially measured cost comprises initial amount lease liability adjusted payments made lease commencement date includes initial direct costs incurred expected costs obligations dismantle remove refurbish underlying asset less incentives received rightofuse assets depreciated straightline basis lease commencement date shorter lease term useful life underlying asset rightofuse assets assessed impairment whenever indication impairment group lessee policy applicable january group classified leases substantially transferred risks rewards ownership finance leases finance leases capitalised property plant equipment start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases classified operating leases operating leases existed substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period leasefinance report notes roche group consolidated financial statements roche group group lessor certain assets mainly diagnostics instruments leased thirdparty customers finance operating lease arrangements transactions may entered separate contracts combined contracts including reagents consumables services treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred case lease finance lease operating lease arrangements take legal form lease nevertheless convey right use asset also covered assessments finance leases finance lease assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent lease revenue entirely based variable lease payments subject subsequent reagent sales recognised performance obligations reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise mergers acquisitions business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations date acquisition group initially recognises individual identifiable assets acquired liabilities assumed cost group date acquisition allocated individual identifiable assets liabilities basis relative fair values date acquisition subsequent consideration performancerelated development milestones recognised intangible assets specific milestones achieved transactions give rise goodwill material directly attributable acquisitionrelated costs included cost acquired assets goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value commercial software development costs capitalised certain recognition criteria technical feasibility commercial viability met available use intangible assets amortised straightline basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years roche group notes roche group consolidated financial statements finance report impairment property plant equipment rightofuse assets intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciationamortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cashgenerating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process intermediates includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses receivables including accounts receivable receivables carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances receivable represents right consideration unconditional excludes contract assets allowance doubtful accounts recorded expected credit losses term receivables estimates based specific indicators ageing customer balances specific credit circumstances groups historical loss rates category customers adjusted forwardlooking macroeconomic data expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience receivables written either partly full reasonable expectation recovery receivables written group continues engage enforcement activities attempt recover receivable due recoveries made recognised profit loss trade lease receivables group applies simplified approach prescribed ifrs requirespermits use lifetime expected loss provision initial recognition receivables group measures allowance doubtful accounts equal credit losses expected lifetime trade lease receivables cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisitionfinance report notes roche group consolidated financial statements roche group provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments group classifies financial instruments following measurement categories disclosed note amortised cost fair value oci fair value oci equity investments fair value profit loss including hedging instruments classification depends groups business model managing financial assets contractual terms cash flows group reclassifies debt securities financial assets amortised cost business model managing assets changes initial recognition group measures financial asset fair value plus case financial asset fair value profit loss transaction costs directly attributable acquisition financial asset transaction costs financial assets carried fair value profit loss expensed profit loss amortised cost assets held collection contractual cash flows cash flows represent solely payments principal interest measured amortised cost less provision impairment gain loss debt security subsequently measured amortised cost part hedging relationship recognised profit loss asset derecognised impaired interest income financial assets included financial income using effective interest rate method assets amortised cost mainly comprised accounts receivable cash cash equivalents time accounts three months fair value comprehensive income fair value oci financial assets held collection contractual cash flows selling financial assets assets cash flows represent solely payments principal interest initially recorded subsequently carried fair value changes fair value recorded comprehensive income except recognition impairment gains losses interest revenue foreign exchange gains losses recognised profit loss financial asset derecognised cumulative gain loss previously recognised oci reclassified equity profit loss interest income financial assets included financial income using effective interest rate method fair value comprehensive income assets mainly comprised money market instruments debt securities equity investments fair value comprehensive income fair value oci equity investments private biotechnology companies kept part groups strategic alliance efforts assets subsequently measured fair value dividends recognised financial income profit loss unless dividend clearly represents recovery part cost investment net gains losses recognised oci included fair value reserve asset derecognised cumulative gain loss previously recognised oci reclassified within equity fair value reserve retained earnings never profit loss roche group notes roche group consolidated financial statements finance report fair value profit loss financial assets whose performance evaluated fair value basis gain loss financial asset subsequently measured fair value profit loss part hedging relationship recognised profit loss presented within financial income expense period arises fair value profit loss assets mainly comprised equity investmentssecurities contingent consideration liabilities initially recorded subsequently carried fair value changes fair value recorded general administration within operating results income statement fair value profit loss hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value less transaction costs subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method derecognition financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire impairment financial assets group recognises loss allowances expected credit losses ecl financial assets measured amortised cost debt securities measured fair value oci trade lease receivables group measures allowance doubtful accounts amount equal lifetime ecl debt securities carried fair value oci debt securities financial assets amortised cost determined low credit risk based external credit ratings counterparties group measures loss allowances amount equal month ecl group considers debt securities low credit risk credit risk rating equivalent globally understood definition investment grade group considers least baa moodys bbb standard poors credit risk debt securities carried fair value oci debt securities financial assets amortised cost increased significantly since initial recognition group measures loss allowances amount equal lifetime ecl group assumes credit risk instruments increased significantly days past due financial assets written either partially full realistic prospect recovery generally case group determines customer assets sources income could generate sufficient cash flows repay amounts subject writeoff however financial assets written still subject enforcement activities order comply groups policy recovery amounts due hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions eligibility hedging hedged instruments formal designation documentation well hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expensefinance report notes roche group consolidated financial statements roche group cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecasted transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future amount tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group implemented various minor amendments existing standards interpretations material impact groups overall results financial position amendments ifrs business combinations definition business mandatorily applicable early adopted group future new revised standards group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory roche group report roche management internal control financial reporting finance report report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa christoph franz alan hippe chairman board directors chief financial officer basel february finance report statutory auditors report roche group statutory auditors report general meeting roche holding ltd basel report audit consolidated financial statements opinion audited consolidated financial statements roche holding ltd subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement comprehensive income consolidated statement changes equity consolidated statement cash flows year ended notes consolidated financial statements including summary significant accounting policies opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law basis opinion conducted audit accordance swiss law international standards auditing isas swiss auditing standards responsibilities provisions standards described auditors responsibilities audit consolidated financial statements section report independent group accordance provisions swiss law requirements swiss audit profession well international ethics standards board accountants international code ethics professional accountants including international independence standards iesba code fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters chargebacks rebates sales returns us pharmaceuticals business carrying value product intangible assets income tax uncertain tax positions acquisition spark therapeutics inc key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion matters roche group statutory auditors report finance report chargebacks rebates sales returns us pharmaceuticals business key audit matter response groups pharmaceuticals business makes sales various audit procedures included amongst others sample customers us fall certain commercial basis obtaining managements calculations accrued governmentmandated contracts purchasing liabilities provisions accounts receivable deductions reimbursement arrangements significant testing accuracy calculations assessing medicaid b drug discount program appropriateness key inputs assumptions used group also provides right return us customers estimates performing assessment referenced certain products return periods cases internal external sources information including extend several years future arrangements terms applicable contracts us government pricing result deductions gross amounts invoiced arriving information historical rates chargebacks rebates revenue create obligations group provide historical rates sales returns consideration current customers credits chargebacks rebate payments trends estimated amounts deducted gross sales recorded accrued liabilities rebates provisions also evaluated accuracy managements estimates sales returns deduction accounts receivable comparing rates used historical estimates rates chargebacks estimates based analyses actual rebate payments chargebacks assessed existing contractual legislatively mandated obligations changes accrual rates used within estimates recent trends historical experience comparing accrual rates current chargeback rebate payment sales return trends management determined accrued liabilities deductions accounts receivable expected also evaluated appropriateness groups chargebacks rebates predominantly medicaid revenue recognition accounting policies including chf million necessary december recognition measurement deductions gross sales additionally provisions sales returns mainly relating relating chargebacks rebates sales returns products near loss exclusivity chf million related disclosures recorded december focused area arrangements complex establishing appropriate yearend position requires significant judgement estimation management assumptions required estimating provisions sales returns also made complicated given recent loss exclusivity us groups pharmaceutical products information chargebacks rebates sales returns us pharmaceuticals business refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note revenue note accounts receivable note current liabilities note provisions contingent liabilitiesfinance report statutory auditors report roche group carrying value product intangible assets key audit matter response group significant product intangible assets audit procedures included amongst others challenging december chf million acquired robustness key assumptions used determine business combinations asset acquisitions inlicensing recoverable amounts including forecast revenues arrangements comprise product intangibles use useful lives discount rates challenge based chf million amortised product intangibles understanding commercial prospects available use chf million amortised individual products well relevant business areas impairment assessment carried product markets operate used valuation intangibles evidence asset may specialists assist us evaluating assumptions impaired intangible assets yet available methodologies used management relation use also tested impairment annually discount rates assessed key inputs projected pricing volumes products projected share product intangibles use chf million predominantly therapeutic area vitro diagnostic market comparing relate acquired products launched relevant assumptions industry forecasts reviewing key risk ability successfully commercialise analyst commentaries retrospective assessment products concerned key estimates assumptions include accuracy previous projections compared revenue growth timing impact loss exclusivity managements assumptions external data discount rates development commercialisation available performed sensitivity analysis individual competing products drivers revenue growth include intangible asset impairment models assess level persistence rate treatment rate market share sensitivity key assumptions could focus work areas assess managements allowance risk product intangibles available use chf million mostly represent inprocess research development addition product intangibles yet available assets due inherent uncertainties research use audit included assessing reasonableness development processes intangible assets available managements assumptions regarding probability use particularly risk impairment impairment obtaining regulatory approval comparison industry assessment requires management make key assumptions practice past history consideration groups judgements clinical technical commercial internal governance approval processes viability new products accordingly also focused audit work areas risks include inability achieve successful trial results obtain required clinical regulatory approvals highly competitive business environment therapeutic areas group significant assets research development information carrying value product intangible assets refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assets roche group statutory auditors report finance report income tax uncertain tax positions key audit matter response group operates across wide range different tax audit procedures included amongst others obtaining jurisdictions around world thus tax treatments understanding uncertain tax positions inquiry tax filings subject challenge local tax authorities employees tax department management respect crossborder transfer pricing arrangements affiliates inspected documentation relation tax goods services financing transactionrelated tax exposure items including correspondence tax authorities matters connection integration investments reports issued tax advisors verify whether uncertain divestments licensing contracts tax treatments tax positions considered provided involving uncertainty include agreements transfer pricing necessary arrangements affiliates involved groups global manufacturing supply chains significant items challenged managements judgement regarding eventual resolution probable tax authority accept uncertainties assistance local country tax treatment tax liability recognised financial specialists reperformed calculation estimated statements reflects managements best estimate exposure inspected thirdparty transfer pricing studies outcome based facts known relevant evaluated applicable past experience jurisdiction group open tax transfer pricing managements interactions tax authorities matters various tax authorities range respective jurisdiction additionally used tax possible outcomes broad december specialists expertise assess appropriateness group recognised current income tax liabilities key assumptions made management conclude chf million includes accruals uncertain best estimate outcome tax positions audit approach included additional audit procedures focused area uncertainty regarding performed group level consider uncertain tax positions estimates amounts tax receivable payable arising group particular respect transfer therefore require significant level expertise pricing arrangements goods services transaction judgement related tax matters information uncertain tax positions refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note income taxesfinance report statutory auditors report roche group acquisition spark therapeutics inc key audit matter response group acquired spark therapeutics inc spark audit procedures relation acquisition december total consideration spark included amongst others inspection legal chf million consideration primarily allocated agreements supporting transaction also examined intangible assets chf million residual information contained within due diligence valuation chf million recognised goodwill reports well internal management presentations board directors management required apply judgement identifying valuing intangible assets deferred tax assets challenged appropriateness methodology purchase price allocation exercise allocation assumptions used management value identified goodwill arising transaction appropriate cash intangible assets support valuation generating unit tax specialists evaluated appropriateness discount rate cost debt tax rate applied key assumptions relating valuation intangible life science expert assisted us challenging key assumptions assets included probability technical success revenue made management determining revenue growth forecasts considering competitive environment discount probability technical success competitive environment rate cost debt tax rate specifically relates two largest intangible assets identified goodwill arising transaction attributed roche pharmaceuticals cashgenerating unit challenged key assumptions based sector reflects benefits groups research expertise reference available industry forecasts development activities haemophilia treatment field analysts commentaries compared managements well access sparks gene therapy expertise assumptions external data available performed sensitivity analysis key assumptions identify likely lead material misstatement could focus work assess managements allowance risk throughout procedures challenged managements external valuers obtained understanding sparks integrated gene therapy platform comprises multiple elements including inlicensed inhouse developed technologies expertise knowhow spark personnel processes areas vector design vector manufacturing investigational new drug enabling studies regulatory processes gene therapy challenged level goodwill recognised assessed appropriateness managements decision allocate goodwill roche pharmaceuticals cashgenerating unit based expected synergies would used within roche business also assessed whether groups disclosures relation acquisition meet requirements relevant accounting standards information acquisition spark therapeutics inc refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures mergers acquisitions note roche group statutory auditors report finance report information annual report board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon opinion consolidated financial statements cover information annual report express form assurance conclusion thereon connection audit consolidated financial statements responsibility read information annual report consider whether information materially inconsistent consolidated financial statements knowledge obtained audit otherwise appears materially misstated based work performed conclude material misstatement information required report fact nothing report regard responsibility board directors consolidated financial statements board directors responsible preparation consolidated financial statements give true fair view accordance ifrs provisions swiss law internal control board directors determines necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements board directors responsible assessing groups ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic alternative auditors responsibilities audit consolidated financial statements objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness groups internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentationfinance report statutory auditors report roche group obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable actions taken eliminate threats safeguards applied matters communicated board directors relevant committee determine matters significance audit consolidated financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firms affiliated kpmg international limited private english company limited guarantee rights reserved roche group multiyear overview supplementary information finance report multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied dividend proposed board directors retrospectivelyfinance report multiyear overview supplementary information roche group multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied dividend proposed board directors retrospectively roche group multiyear overview supplementary information finance report sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total finance report multiyear overview supplementary information roche group additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information finance report alternative performance measures financial information included financial review includes certain alternative performance measures apms accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms presented financial review relate performance current year comparative periods core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note excluding commercial software intangible assets impairment goodwill see note excluded acquisition accounting impacts accounting merger acquisition transactions alliance arrangements see financial review excluded discontinued operations currently none excluded legal environmental cases see financial review excluded global issues outside healthcare sector beyond groups control excluded material treasury items major debt restructurings currently none excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial reviewfinance report multiyear overview supplementary information roche group core results reconciliation millions chf intan intan pension normali global gibles gibles alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs turing sation ment actions mental ments issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf intan intan pension normali global gibles gibles alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs turing sation ment actions mental ments issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche group multiyear overview supplementary information finance report divisional core results reconciliation millions chf intan intan pension global gibles gibles alliance legal plan restruc amorti impair trans environ settle ifrs turing sation ment actions mental ments core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf intan intan pension global gibles gibles alliance legal plan restruc amorti impair trans environ settle ifrs turing sation ment actions mental ments core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit finance report multiyear overview supplementary information roche group core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business operating free cash flow calculated based ifrs operating profit adjusted certain noncash items movements net working capital capital expenditures investments property plant equipment intangible assets well principal portion lease liabilities paid leased assets operating free cash flow different cash flows operating activities defined ias includes capital expenditures within responsibility divisional management excludes income taxes paid within responsibility divisional management cash outflows defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflows financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments roche group multiyear overview supplementary information finance report operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review operating free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets pensions postemployment benefits add back total payments defined benefit plans deduct allocation payments operating free cash flow acquisitionrelated items including transaction costs operating items operating free cash flow free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets interest paid operating items including acquisitionrelated items treasury items free cash flow finance report multiyear overview supplementary information roche group supplementary information used calculate divisional operating free cash flow shown table divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments roche group multiyear overview supplementary information finance report ebitda group use earnings interest tax depreciation amortisation ebitda either internal management reporting external communications opinion groups management operating free cash flow gives useful consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade receivables inventories certain noncash entries arising acquisition accounting pension accounting operating free cash flow also includes cash used investments property plant equipment leased assets intangible assets whereas ebitda excludes costs cash outflows items convenience readers use ebitda provided table starting point uses core results already exclude amortisation impairment goodwill intangible assets ebitda using core results millions chf pharmaceuticals diagnostics corporate group ebitda core operating profit depreciation impairment property plant equipment core basis depreciation impairment rightofuse assets core basis ebitda margin sales finance report multiyear overview supplementary information roche group net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment leased assets rightofuse assets goodwill intangible assets net working capital longterm net operating assets minus provisions calculation net operating assets disclosed note annual financial statements shown tables net operating assets reconciliation millions chf treasury pharmaceuticals diagnostics corporate taxation group property plant equipment rightofuse assets goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets reconciliation millions chf treasury pharmaceuticals diagnostics corporate taxation group property plant equipment rightofuse assets goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets roche group multiyear overview supplementary information finance report net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt calculations including details movements current year shown table financial review net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earnings per share disclosures countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflatedfinance report roche securities roche group roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr standard poors index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july roche group roche securities finance report number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors stock codes share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypkfinance report roche holding ltd basel roche holding ltd basel financial statements notes financial statements summary significant accounting policies significant shareholders hareholders equity fulltime equivalent employees contingent liabilities board executive shareholdings appropriation available earnings statutory auditors report general meeting roche holding ltd basel roche holding ltd basel financial statements finance report financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies interestbearing liabilities group companies shortterm liabilities total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities genussscheine nominal valuefinance report financial statements roche holding ltd basel income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income roche holding ltd basel notes financial statements finance report notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant accounting principles applied described company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments direct indirect investments company listed note roche group annual financial statements listing excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation ownership interests equal voting rights taxes direct taxes include corporate income capital taxesfinance report notes financial statements roche holding ltd basel shareholders equity share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates equity instruments december company hold roche shares nonvoting equity securities none company neither purchased sold roche shares nonvoting equity securities company subsidiaries meet definitions requirements article b co hold equity instruments within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co movement recognised amounts millions chf voluntary reserves retained earnings legal retained special available equity share capital earnings free reserve reserve earnings instruments total equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments december roche holding ltd basel notes financial statements finance report contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper notes credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis holding ag basel participation fulltime equivalent employees annual average number fulltime equivalent employees exceed ten peoplefinance report notes financial statements roche holding ltd basel board executive shareholdings board directors directors mr andr hoffmann dr jrg duschmal certain members founders families closely associated belong shareholder group pooled voting rights dr andreas oeri previously member board directors stand reelection annual general meeting end shareholder group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine c franz hoffmann j bell na na j brown p bulcke h clevers j duschmal na na p frost na na hauser r p lifton e oeri na na b poussot schwan b c suessmuth dyckerhoff c c total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative close relatives hauser held nonvoting equity securities genussscheine e r p lifton held roche american depositary receipts adrs eight adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july corporate executive committee end year members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b anderson hippe g keller na na b schinecker c wilbur total equity compensation awards ssars rsus roche performance share plan b december close relatives dr keller held roche shares roche holding ltd basel notes financial statements finance report remuneration equity compensation plans members corporate executive committee complemented restricted stock units rsus since composed stocksettled stock appreciation rights ssars rsus new performance share plan psp awards granted december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information given remuneration report included annual report pages ssars awards granted members corporate executive committee vest four years awards granted vest three years ssars awards held december year issue total schwan b anderson hippe schinecker c wilbur total strike price chf expiry date mar mar mar mar mar mar mar december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information given remuneration report included annual report pages rsu awards granted members corporate executive committee vest four years awards granted vest three years thereafter nonvoting equity securities andor shares may remain blocked ten years rsu awards held december year issue total schwan b anderson hippe schinecker c wilbur total december members corporate executive committee hold performance share plan psp awards terms vesting conditions awards remaining cycle disclosed note roche group annual financial statements additional supplementary information given remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end remaining cycle performance targets achieved accordingly participants receive originally targeted nonvoting equity securities new psp awards granted members corporate executive committee information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statementsfinance report appropriation available earnings roche holding ltd basel appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche holding ltd basel statutory auditors report finance report statutory auditors report general meeting roche holding ltd basel report audit financial statements opinion audited financial statements roche holding ltd comprise balance sheet december income statement year ended notes financial statements including summary significant accounting policies opinion financial statements pages year ended december comply swiss law companys articles incorporation basis opinion conducted audit accordance swiss law swiss auditing standards responsibilities provisions standards described auditors responsibilities audit financial statements section report independent entity accordance provisions swiss law requirements swiss audit profession fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion report key audit matters based circular federal audit oversight authority key audit matters matters professional judgement significance audit financial statements current period determined key audit matters communicate report responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud error preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate entity cease operations realistic alternative auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis financial statementsfinance report statutory auditors report roche holding ltd basel part audit accordance swiss law swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause entity cease continue going concern communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firms affiliated kpmg international limited private english company limited guarantee rights reservedpublished cautionary statement regarding forwardlooking statements f hoffmannla roche ltd finance report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing media relations products market fluctuations currency exchange rates tel general financial market conditions uncertainties email mediarelationsrochecom discovery development marketing new products new uses existing products including without limitation negative results investor relations clinical trials research projects unexpected side effects tel pipeline marketed products increased government pricing email investorrelationsrochecom pressures interruptions production loss inability obtain adequate protection intellectual property rights corporate sustainability committee litigation loss key executives employees tel adverse publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified paperf hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom troper ecnanif e roche finance report